<SEC-DOCUMENT>0001683168-25-003362.txt : 20250512
<SEC-HEADER>0001683168-25-003362.hdr.sgml : 20250512
<ACCEPTANCE-DATETIME>20250512060310
ACCESSION NUMBER:		0001683168-25-003362
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		14
FILED AS OF DATE:		20250512
DATE AS OF CHANGE:		20250512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CNS Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001729427
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				822318545
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-286529
		FILM NUMBER:		25932385

	BUSINESS ADDRESS:	
		STREET 1:		2100 WEST LOOP SOUTH
		STREET 2:		SUITE 900
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77027
		BUSINESS PHONE:		1-800-946-9185

	MAIL ADDRESS:	
		STREET 1:		2100 WEST LOOP SOUTH
		STREET 2:		SUITE 900
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77027
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>cns_s1a1.htm
<DESCRIPTION>AMENDMENT NO. 1 TO FORM S-1
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:CNSP="http://cnspharma.com/20250512">
<head>
     <title>CNS Pharmaceuticals, Inc. S-1</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_031_CNSP_cnspharma.com_20250512 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20250512_20250512 -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DAmendmentFlag_true -->
<!-- Field: Set; Name: xdx; ID: xdx_05B_edei%2D%2DAmendmentDescription_client made edits.  -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0001729427 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-05-12" id="Fact000003" name="dei:AmendmentFlag">true</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-05-12" id="Fact000004" name="dei:AmendmentDescription">client made edits.</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-05-12" id="Fact000005" name="dei:EntityCentralIndexKey">0001729427</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-05-12" id="xdx2ixbrl0010" name="dei:DocumentType">S-1/A</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="cnsp-20250512.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-05-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001729427</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-12</xbrli:startDate>
        <xbrli:endDate>2025-05-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>As filed with the Securities and Exchange Commission on May
12, 2025.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><b>Registration No. 333-286529</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNITED STATES </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>AMENDMENT NO. 1 TO</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>FORM <span id="xdx_900_edei--DocumentType_dxL_c20250512__20250512_zkUDSWq406h9" title="::XDX::S-1%2FA"><span style="-sec-ix-hidden: xdx2ixbrl0010">S-1</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>REGISTRATION STATEMENT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><i>UNDER </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><i>THE SECURITIES ACT OF 1933</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><i>&#160;</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span id="xdx_90F_edei--EntityRegistrantName_c20250512__20250512_zjA9F7B8tU4i"><ix:nonNumeric contextRef="AsOf2025-05-12" id="Fact000011" name="dei:EntityRegistrantName">CNS Pharmaceuticals, Inc.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in Its Charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 33%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityIncorporationStateCountryCode_c20250512__20250512_zk1cKJHKrN7e"><ix:nonNumeric contextRef="AsOf2025-05-12" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="width: 34%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2834</b></span></td>
    <td style="width: 33%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityTaxIdentificationNumber_c20250512__20250512_zmWN3AE5XeHe"><ix:nonNumeric contextRef="AsOf2025-05-12" id="Fact000013" name="dei:EntityTaxIdentificationNumber">82-2318545</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or Other Jurisdiction of</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Incorporation or Organization)</p></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Primary Standard Industrial</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Classification Code Number)</p></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(I.R.S. Employer</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification Number)</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90A_edei--EntityAddressAddressLine1_c20250512__20250512_z7UG5XvorJM1"><ix:nonNumeric contextRef="AsOf2025-05-12" id="Fact000014" name="dei:EntityAddressAddressLine1">2100 West Loop South</ix:nonNumeric></span>, <span id="xdx_902_edei--EntityAddressAddressLine2_c20250512__20250512_zjW6sL6MadGl"><ix:nonNumeric contextRef="AsOf2025-05-12" id="Fact000015" name="dei:EntityAddressAddressLine2">Suite 900</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90F_edei--EntityAddressCityOrTown_c20250512__20250512_zQt0EOGWTTg8"><ix:nonNumeric contextRef="AsOf2025-05-12" id="Fact000016" name="dei:EntityAddressCityOrTown">Houston</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressStateOrProvince_c20250512__20250512_zOX03NQSYaHc"><ix:nonNumeric contextRef="AsOf2025-05-12" id="Fact000017" name="dei:EntityAddressStateOrProvince">TX</ix:nonNumeric></span> <span id="xdx_90A_edei--EntityAddressPostalZipCode_c20250512__20250512_zc4gFeebstb6"><ix:nonNumeric contextRef="AsOf2025-05-12" id="Fact000018" name="dei:EntityAddressPostalZipCode">77027</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90F_edei--CityAreaCode_c20250512__20250512_z1evtS0OXHg9"><ix:nonNumeric contextRef="AsOf2025-05-12" id="Fact000019" name="dei:CityAreaCode">(800)</ix:nonNumeric></span> <span id="xdx_909_edei--LocalPhoneNumber_c20250512__20250512_zGrLLzCmCm73"><ix:nonNumeric contextRef="AsOf2025-05-12" id="Fact000020" name="dei:LocalPhoneNumber">946-9185</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address, Including Zip Code, and Telephone Number,
Including Area Code, of Registrant&#8217;s Principal Executive Offices)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Mr. John Climaco</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Chief Executive Officer </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2100 West Loop South, Suite 900</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Houston, TX 77027</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(800) 946-9185</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name, Address, Including Zip Code, and Telephone
Number, Including Area Code, of Agent For Service)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Copies to:</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 50%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Cavas S. Pavri</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Johnathan Duncan</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ArentFox Schiff LLP</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">1717 K Street NW</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, DC 20006</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Telephone: <span style="text-transform: uppercase">(202)&#160;724-6847</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Fax: (202) 778-6460</p></td>
    <td style="width: 50%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 10.1pt">Ron Ben-Bassat</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 10.1pt">Eric Victorson</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 10.1pt">Sullivan &amp; Worcester LLP</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 10.1pt">1251 Avenue of the Americas</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 10.1pt">New York, NY 10020</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 10.1pt">Telephone: (212) 660-3000</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt"><b>Approximate date of commencement
of proposed sale to the public:</b> As soon as practicable after the effective date of this Registration Statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt">If any of the securities
being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933,
check the following box. &#9746;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt">If this form is filed to
register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt">If this form is a post-effective
amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt">If this form is a post-effective
amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt">Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging
growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting
company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 16%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large&#160;accelerated filer</span></td>
    <td style="width: 48%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="width: 31%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</span></td>
    <td style="width: 5%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--EntityFilerCategory_c20250512__20250512_zKVjeHAGgnD8"><ix:nonNumeric contextRef="AsOf2025-05-12" format="ixt-sec:entityfilercategoryen" id="Fact000021" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span></span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller&#160;reporting company</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--EntitySmallBusiness_c20250512__20250512_zLrToKU6rANd"><ix:nonNumeric contextRef="AsOf2025-05-12" format="ixt:booleantrue" id="Fact000022" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--EntityEmergingGrowthCompany_c20250512__20250512_z1sfRtFBwNAd"><ix:nonNumeric contextRef="AsOf2025-05-12" format="ixt:booleantrue" id="Fact000023" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. <span id="xdx_907_edei--EntityExTransitionPeriod_c20250512__20250512_zn13bFNzAvse"><ix:nonNumeric contextRef="AsOf2025-05-12" format="ixt:booleanfalse" id="Fact000024" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>The Registrant hereby
amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file
a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&#160;8(a)
of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant
to said Section&#160;8(a), may determine.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red; text-align: justify"><b>The information in this preliminary prospectus
is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange
Commission is effective. This preliminary prospectus is not an offer to sell these securities and we are not soliciting offers to buy
these securities in any jurisdiction where the offer or sale is not permitted. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 34%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><b>Preliminary
    Prospectus</b></span></td>
    <td style="width: 33%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><b>Subject
    to Completion</b></span></td>
    <td style="width: 33%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><b>Dated
    May 12, 2025</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Up to 6,250,000 Shares of Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Up to 6,250,000 Pre-Funded Warrants to Purchase
up to 6,250,000 Shares of Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Up to 6,250,000 Series F Common Warrants
to Purchase up to 6,250,000 Shares of Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Up to 6,250,000 Shares of Common Stock Underlying
such Pre-Funded Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Up to 6,250,000 Shares of Common Stock Underlying
such Series F Common Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CNS Pharmaceuticals, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We
                                            are offering on a reasonable best efforts basis up to 6,250,000 shares of our common stock
                                            together with series F warrants (each, a &#8220;Series F warrant&#8221; or &#8220;common
                                            warrant&#8221;) to purchase up to 6,250,000 shares of our common stock based on an assumed
                                            combined public offering price of $1.12 per share and accompanying common warrant (the last
                                            reported sale price of our common stock on The Nasdaq Capital Market (&#8220;Nasdaq&#8221;)
                                            on May 8, 2025). Each common warrant will be exercisable for one share of our common stock
                                            and have an assumed exercise price of $1.12 per share (or 100% of the assumed offering price
                                            per share and accompanying common warrant). Each common warrant will be exercisable beginning
                                            on the effective date of stockholder approval of the issuance of the shares upon exercise
                                            of the common warrants (the &#8220;Warrant Stockholder Approval&#8221;), provided however,
                                            if the Pricing Conditions (as defined below) are met, the Warrant Stockholder Approval will
                                            not be required and the common warrant will be exercisable upon issuance (the &#8220;Initial
                                            Exercise Date&#8221;). The Series F warrants will expire five years from the Initial Exercise
                                            Date or the Warrant Stockholder Approval, as applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The shares of common stock
and common warrants will be issued separately and will be immediately separable upon issuance but will be purchased together in this offering.
This prospectus also relates to the shares of common stock issuable upon exercise of the common warrants sold in this offering. As used
herein &#8220;Pricing Conditions&#8221; means that the combined public offering price per share and accompanying common warrant is such
that the Warrant Stockholder Approval is not required under the rules of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) because either
(i) the offering is an at-the-market offering under the rules of Nasdaq (the &#8220;Nasdaq Rules&#8221;) and such price equals or exceeds
the sum of (a) the applicable &#8220;Minimum Price&#8221; per share under Nasdaq Rule 5635(d) plus (b) $0.125 per whole share of common
stock underlying the common warrants or (ii) the offering is a discounted offering where the pricing and discount (including attributing
a value of $0.125 per whole share underlying the common warrants) meet the pricing requirements under the Nasdaq Rules.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We
                                            are also offering pre-funded warrants (the &#8220;pre-funded warrants&#8221; and together
                                            with the common warrants, the &#8220;warrants&#8221;) to purchase up to 6,250,000 shares
                                            of common stock to those investors whose purchase of shares of common stock in this offering
                                            would result in the purchaser, together with its affiliates and certain related parties,
                                            beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our
                                            outstanding common stock immediately following the consummation of this offering, in lieu
                                            of shares of common stock that would result in beneficial ownership in excess of 4.99% (or,
                                            at the election of the purchaser, 9.99%) of our outstanding common stock. Each pre-funded
                                            warrant is exercisable for one share of common stock and has an exercise price of $0.001
                                            per share. The combined purchase price per pre-funded warrant and accompanying common warrant
                                            is equal to $1.119, which is equal to the combined purchase price per share of common stock
                                            and accompanying common warrant less $0.001. Each pre-funded warrant will be exercisable
                                            immediately upon issuance and may be exercised at any time until exercised in full. The pre-funded
                                            warrants and common warrants will be issued separately and will be immediately separable
                                            upon issuance but will be purchased together in this offering. For each pre-funded warrant
                                            we sell, the number of shares of common stock we are offering will be decreased on a one-for-one
                                            basis. This prospectus also relates to the shares of common stock issuable upon exercise
                                            of the pre-funded warrants sold in this offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We refer to the common stock
and warrants to be sold in this offering collectively as the &#8220;securities.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These securities are being
sold in this offering to certain purchasers under a securities purchase agreement between us and such purchasers. The securities are
expected to be issued in a single closing and the combined public offering price per share of common stock or pre-funded warrant and
accompanying common warrant will be fixed for the duration of this offering. We will deliver all securities to be issued in connection
with this offering delivery versus payment or receipt versus payment, as the case may be, upon receipt of investor funds received by
us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our
                                            common stock is listed on the Nasdaq Capital Market under the symbol &#8220;CNSP.&#8221;
                                            On May 8, 2025, the last reported sale price of our common stock on Nasdaq was $1.12 per
                                            share. The actual number of securities, the combined offering price per share of common stock
                                            or pre-funded warrant and accompanying common warrant and the exercise price per share of
                                            common stock for the accompanying common warrant will be as determined between us, the placement
                                            agent and the investors in this offering based on market conditions at the time of pricing.
                                            Therefore, the recent market price used throughout this prospectus may not be indicative
                                            of the actual public offering price for the securities, which may be substantially lower
                                            than the assumed price used in this prospectus. There is no established public trading market
                                            for the warrants and we do not expect a market to develop. In addition, we do not intend
                                            to apply for a listing of the warrants on any national securities exchange or other trading
                                            system.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have engaged A.G.P./Alliance
Global Partners to act as our sole placement agent (the &#8220;placement agent&#8221;) in connection with this offering. The placement
agent has agreed to use its reasonable best efforts to arrange for the sale of the securities offered by this prospectus. The placement
agent is not purchasing or selling any of the securities we are offering and the placement agent is not required to arrange the purchase
or sale of any specific number of securities or dollar amount. We have agreed to compensate the placement agent as set forth in the table
below, which assumes that we sell all of the securities offered by this prospectus. Because there is no minimum number of securities
or minimum aggregate amount of proceeds for this offering to close, we may sell fewer than all of the securities offered hereby, and
investors in this offering will not receive a refund in the event that we do not sell an amount of securities sufficient to pursue the
business goals outlined in this prospectus. Because there is no escrow account and there is no minimum offering amount, investors could
be in a position where they have invested in our company, but we are unable to fulfill our objectives due to a lack of interest in this
offering. Also, any proceeds from the sale of securities offered by us will be available for our immediate use, despite uncertainty about
whether we would be able to use such funds to effectively implement our business plan. This offering will end no later than May 30, 2025,
except that the shares of common stock underlying the warrants will be offered on a continuous basis pursuant to Rule 415 under the Securities
Act of 1933, as amended (the &#8220;Securities Act&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should read this prospectus,
together with additional information described under the headings &#8220;<a href="#a_019">Incorporation of Certain Information by Reference</a>&#8221; and
&#8220;<a href="#a_020">Where You Can Find More Information</a>,&#8221; carefully before you invest in any of our securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an &#8220;emerging
growth company&#8221; as defined in Section 2(a) of the Securities Act and we have elected to comply with certain reduced public company
reporting requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Investing in our
securities involves a high degree of risk. See the section entitled &#8220;<a href="#a_004">Risk Factors</a>&#8221; beginning on
page 7 of this prospectus for a discussion of risks that should be considered in connection with an investment in our
securities.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Neither the Securities
and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy
of this prospectus. Any representation to the contrary is a criminal offense. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Per Share and</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>accompanying</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Common Warrant</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Per Pre-Funded</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Warrant and</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>accompanying</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Common Warrant</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 52%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public offering price</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement Agent fees <sup>(1)</sup></span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds to us, before expenses<sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td style="width: 98%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have agreed to pay the placement agent a cash fee equal to 7.0% of the aggregate proceeds of this offering and to reimburse the placement agent for certain of its offering-related expenses. See &#8220;<a href="#a_016">Plan of Distribution</a>&#8221; beginning on page 24 of this prospectus for a description of the compensation to be received by the placement agent.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amount of the proceeds to us presented in this table does not give effect to any exercise of the warrants.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Delivery of the shares and warrants is expected to be made on or about
__________, 2025, subject to satisfaction of customary closing conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>__________________</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>Sole Placement Agent</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 100%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b>A.G.P.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>The date of this prospectus is &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
2025</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;&#160;</b></span></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b><span id="a_001"></span>Table
of Contents </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT THIS PROSPECTUS</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="width: 94%"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS SUMMARY</span></a></td>
    <td style="width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</span></a></td>
    <td style="text-align: center">7</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAUTIONARY NOTE REGARDING FORWARD-LOOKING
    STATEMENTS</span></a></td>
    <td style="text-align: center">11</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE OF PROCEEDS</span></a></td>
    <td style="text-align: center">13</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DILUTION</span></a></td>
    <td style="text-align: center">14</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAPITALIZATION</span></a></td>
    <td style="text-align: center">15</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL
    OWNERS AND MANAGEMENT</span></a></td>
    <td style="text-align: center">16</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF CAPITAL STOCK</span></a></td>
    <td style="text-align: center">18</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF PRE-FUNDED WARRANTS</span></a></td>
    <td style="text-align: center">21</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><a href="#a_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF COMMON WARRANTS</span></a></td>
    <td style="text-align: center">22</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><a href="#a_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLAN OF DISTRIBUTION</span></a></td>
    <td style="text-align: center">24</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><a href="#a_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL MATTERS</span></a></td>
    <td style="text-align: center">28</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><a href="#a_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</span></a></td>
    <td style="text-align: center">28</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><a href="#a_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INCORPORATION OF CERTAIN INFORMATION
    BY REFERENCE</span></a></td>
    <td style="text-align: center">28</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><a href="#a_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</span></a></td>
    <td style="text-align: center">29</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_002"></span>ABOUT THIS PROSPECTUS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus is part of
a registration statement on Form S-1 that we filed with the SEC to register the securities offered hereby under the Securities Act. We
may also file a prospectus supplement or post-effective amendment to the registration statement of which this prospectus forms a part
that may contain material information relating to these offerings. You should carefully read this prospectus before deciding to invest
in our securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not, and the placement
agent has not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus
or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and
can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell
only the securities offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. The information contained
in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or
any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For investors outside the
United States: We have not, and the placement agent has not, done anything that would permit this offering or possession or distribution
of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the
United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the
offering of the securities and the distribution of this prospectus outside the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus may contain
references to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus,
including logos, artwork, and other visual displays, may appear without the &#174; or TM symbols. We do not intend our use or display of
other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No dealer, salesperson or
other person is authorized to give any information or to represent anything not contained in this prospectus. You must not rely on any
unauthorized information or representations. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances
and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus contains estimates
and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry.
We obtained the industry and market data in this prospectus from our own research as well as from industry and general publications, surveys
and studies conducted by third parties. This data involves a number of assumptions and limitations and contains projections and estimates
of the future performance of the industries in which we operate that are subject to a high degree of uncertainty. We caution you not to
give undue weight to such projections, assumptions and estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 1; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b><span id="a_003"></span>Prospectus
Summary</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>This summary highlights
information contained elsewhere in this prospectus. This summary does not contain all of the information that you should consider before
deciding to invest in our securities. You should read this entire prospectus carefully, including the &#8220;<a href="#a_004">Risk Factors</a>&#8221;
section in this prospectus. References in this prospectus to &#8220;we&#8221;, &#8220;us&#8221;, &#8220;its&#8221;, &#8220;our&#8221;
or the &#8220;Company&#8221; are to CNS Pharmaceuticals, Inc., as appropriate to the context.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical pharmaceutical
company organized as a Nevada corporation in July 2017 to focus on the development of anti-cancer drug candidates for the treatment of
brain and central nervous system tumors, based on intellectual property that we license under license agreements with Cortice Biosciences,
Inc. (&#8220;Cortice&#8221;) and own pursuant to a collaboration and asset purchase agreement with Reata Pharmaceuticals, Inc. (&#8220;Reata&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe our drug candidates,
TPI 287 and Berubicin, may be significant developments in the treatment of Glioblastoma and other CNS malignancies, and if approved by
the U.S. Food and Drug Administration (&#8220;FDA&#8221;), could give Glioblastoma patients important new therapeutic alternatives to
the current standard of care. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells making up the supportive
tissue of the brain. These tumors are usually highly malignant (cancerous) because the cells reproduce quickly, and they are supported
by a large network of blood vessels. Berubicin is an anthracycline, which is a class of drugs that are among the most powerful and extensively
used chemotherapy drugs known. TPI 287 is an abeotaxane, and is related to the family of common chemotherapy drugs known as taxanes. Based
on limited clinical and preclinical data, we believe TPI 287 is the first taxane that appears to cross the blood brain barrier (&#8220;BBB&#8221;)
in significant concentrations targeting brain cancer cells. Based on clinical and preclinical data, Berubicin is the first anthracycline
that appears to cross the BBB in significant concentrations targeting brain cancer cells. While our focus is currently on the development
of TPI 287 and Berubicin, we are also in the process of attempting to secure intellectual property rights to additional compounds that
we plan to develop into drugs to treat CNS and other cancers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">TPI 287 had previously been
granted Orphan Drug Designation (&#8220;ODD&#8221;) status by the FDA. ODD from the FDA is available for drugs targeting diseases with
less than 200,000 cases per year. ODD may enable market exclusivity of 7 years from the date of approval of a New Drug Application (&#8220;NDA&#8221;)
in the United States. During that period the FDA generally could not approve another product containing the same drug for the same designated
indication. Orphan drug exclusivity will not bar approval of another product under certain circumstances, including if a subsequent product
with the same active ingredient for the same indication is shown to be clinically superior to the approved product on the basis of greater
efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet
market demand. The ODD strengthens our intellectual property protections although the Company is exploring if there are other patents
that could be filed related to TPI 287 to extend additional protections.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">TPI 287 is an abeotaxane and
is an investigational chemotherapy agent classified as a third-generation taxane derivative. It was developed to address some of the limitations
of earlier taxanes like paclitaxel (Taxol) and docetaxel (Taxotere), particularly issues related to drug resistance and poor penetration
of the BBB. As a synthetic, lipophilic compound, TPI 287 is designed to be brain-penetrant, potentially allowing it to reach CNS tumors
more effectively than its predecessors. Like other taxanes, TPI 287&#8217;s mechanism of action is to stabilize microtubules, which disrupts
cell division and induces apoptosis. However, one of its notable advantages is its reduced susceptibility to drug efflux pumps such as
P-glycoprotein (P-gp), a common mechanism by which cancer cells develop resistance to chemotherapy. This feature gives TPI 287 potential
utility in treating drug-resistant cancers in the CNS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">TPI 287 has been studied in
early-phase clinical trials (Phase I and II) in over 300 patients for several indications, including Glioblastoma, metastatic breast cancer
with brain metastases, non-small cell lung cancer (&#8220;NSCLC&#8221;), castration-resistant prostate cancer, and neuroblastoma. TPI
287 represents a promising candidate for treating cancers involving the CNS, as well as those that have become resistant to traditional
taxane therapies. While it has shown promise in limited clinical trials, further clinical development is necessary to determine its future
in neuro-oncology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Berubicin was discovered at
The University of Texas M.D. Anderson Cancer Center (&#8220;UTMDACC&#8221;) by Dr. Waldemar Priebe, the founder of the Company. Through
a series of transactions, Berubicin was initially licensed to Reata. Reata initiated several Phase I clinical trials with Berubicin for
CNS malignancies, one of which was for malignant gliomas, but subsequently allowed their Investigational New Drug (&#8220;IND&#8221;)
with the FDA to lapse for strategic reasons. This required us to obtain a new IND for Berubicin before beginning further clinical trials.
On December 17, 2020, we announced that our IND application with the FDA for Berubicin for the treatment of Glioblastoma Multiforme was
in effect. We initiated this trial for patient enrollment during the second quarter of 2021 with the first patient dosed during the third
quarter of 2021 to investigate the efficacy of Berubicin in adults with Glioblastoma Multiforme who have failed first-line therapy. The
first patient on the trial was treated during the third quarter of 2021. Correspondence between the Company and the FDA resulted in modifications
to our initial trial design, including designating overall survival (OS) as the primary endpoint of the study. OS is a rigorous endpoint
that the FDA has recognized as a basis for approval of oncology drugs when a statistically significant improvement can be shown relative
to a randomized control arm.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 25, 2025, CNS released
topline data from a primary analysis of a clinical trial being conducted to evaluate the efficacy of Berubicin in patients with Glioblastoma
Multiforme who have failed primary treatment for their disease. The trial, compares the efficacy of Berubicin to that of Lomustine, a
current standard of care in this setting, with a 2 to 1 randomization of the 252 patients to Berubicin or Lomustine. Patients receiving
Berubicin were administered a 2-hour IV infusion of 7.5 mg/m2 berubicin hydrochloride daily for three consecutive days followed by 18
days off (a 21-day cycle). Lomustine is administered orally once every six weeks. The trial design included a pre-planned, non-binding
interim futility analysis. We reached the criteria required by the study protocol to conduct this interim futility analysis, which an
independent Data Safety Monitoring Board (&#8220;DSMB&#8221;) was responsible for conducting. The DSMB&#8217;s charter mandated that they
review the primary endpoint, Overall Survival, as well as secondary endpoints and safety data to determine whether the efficacy data for
the risk-benefit profile warrants modification or discontinuation of the study. On December 18, 2023, we released the DSMB&#8217;s recommendation
which was to continue the study without modification. The recently released topline data showed that although Berubicin produced clinically
relevant outcomes that appear to be comparable (although the trial was not powered to determine non-inferiority) to Lomustine across multiple
endpoints, it did not demonstrate a statistically significant difference in overall survival, the primary endpoint. Nevertheless, given
the dearth of alternative approved therapies for GBM, we believe Berubicin has demonstrated potential value as a possible treatment for
Glioblastoma. As such we are currently evaluating whether any potential paths forward exist for the program. Any such path will be planned
and executed in consultation with the FDA. Even if Berubicin is approved, there is no assurance that patients will choose an infusion
treatment, as compared to the current standard of care, which requires oral administration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have manufacturing
facilities and all manufacturing activities are contracted out to third parties. Additionally, we do not have a sales organization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 21, 2017, we entered
into a Collaboration and Asset Purchase Agreement with Reata (the &#8220;Reata Agreement&#8221;). Pursuant to the Reata Agreement we purchased
all of Reata&#8217;s intellectual property and development data regarding Berubicin, including all trade secrets, knowhow, confidential
information and other intellectual property rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 28, 2017, we obtained
the rights to a worldwide, exclusive royalty-bearing, license to the chemical compound commonly known as Berubicin from HPI in an agreement
we refer to as the HPI License. HPI is affiliated with our founder, Dr. Priebe. Under the HPI License we obtained the exclusive right
to develop certain chemical compounds for use in the treatment of cancer anywhere in the world. In the HPI License we agreed to pay HPI:
(i) development fees of $750,000 over a three-year period beginning November 2019; (ii) a 2% royalty on net sales; (iii) a $50,000 per
year license fee; (iv) milestone payments of $100,000 upon the commencement of a Phase II trial and $1.0 million upon the approval of
a New Drug Application (&#8220;NDA&#8221;) for Berubicin; and (v) 3 shares of our common stock. The patents we licensed from HPI expired
in March 2020. On March 23, 2025, the Company terminated the HPI License.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 10, 2020, the FDA
granted ODD for Berubicin for the treatment of malignant gliomas. The ODD now constitutes our primary intellectual property protections
related to Berubicin although the Company is exploring other patents that could be filed related to Berubicin to extend additional protections.
We believe we have all rights and intellectual property necessary to develop Berubicin. As stated earlier, it is our plan to obtain additional
intellectual property covering other compounds which, subject to the receipt of additional financing, may be developed into drugs for
brain and other cancers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 29, 2024, we entered
into an Exclusive License Agreement and Stock Purchase Agreement (collectively, the &#8220;Cortice Agreements&#8221;) with Cortice Biosciences,
Inc. (&#8220;Cortice&#8221;) pursuant to which Cortice granted us an exclusive license to the intellectual property rights related to
certain patents around the compound TPI 287 in the United States, Canada, Mexico and Japan. The term of the license will expire, other
than due to a breach of the Cortice Agreements, at the end of the royalty term with respect to any licensed product in any of the included
territories, which begins upon the first commercial sale in such territory and ends on the latest of (i) ten years after such sale, (ii)
the expiration of regulatory or marketing exclusivity for such licensed product in such country, or (c) the expiration of the last to
expire valid patent claim in such country covering such licensed product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Company Information </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our principal executive offices
are located at 2100 West Loop South, Suite 900, Houston, TX 77027 and our telephone number is (800) 946-9185. Our website address is www.cnspharma.com.
The information on or accessible through our website is not part of this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<!-- Field: Page; Sequence: 9 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>THE OFFERING</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common stock we are offering</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 62%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up
    to 6,250,000 shares of common stock based on an assumed combined public offering price of $1.12 per share of common stock and accompanying
    common warrant, which is equal to the last sale price of our common stock as reported by Nasdaq on May 8, 2025.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pre-funded warrants we are offering</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are also offering up to 6,250,000 pre-funded warrants to purchase up to 6,250,000 shares of common stock in lieu of shares of common
    stock to any purchaser whose purchase of shares of common stock in this offering would otherwise result in such purchaser, together
    with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the purchaser&#8217;s election, 9.99%)
    of our outstanding common stock immediately following the consummation of this offering. Each pre-funded warrant will be exercisable
    for one share of common stock, will have an exercise price of $0.001 per share, will be immediately exercisable, and may be exercised
    at anytime until exercised in full. This prospectus also relates to the offering of the shares of common stock issuable upon exercise
    of the pre-funded warrants.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common warrants we are offering</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are also offering up to 6,250,000 Series F warrants to purchase up to 6,250,000 shares of common. Each common warrant will be exercisable
    for one share of common stock, will have an exercise price of $1.12 per share (or 100% of the assumed combined public offering price
    per share of common stock and accompanying common warrant). Each common warrant will be exercisable beginning on the effective date
    of the Warrant Stockholder Approval, provided however, if the Pricing Conditions are met, the Warrant Stockholder Approval will not
    be required and the common warrant will be exercisable on the Initial Exercise Date. The Series F warrants will expire five years
    from the Initial Exercise Date or the Warrant Stockholder Approval, as applicable. This prospectus also relates to the offering of
    the shares of common stock issuable upon exercise of the common warrants.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common stock outstanding immediately before this offering</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,944,381 shares</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common stock outstanding immediately after this offering</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,194,381
    shares, assuming no sale of any pre-funded warrants and assuming none of the common warrants issued in this offering are exercised.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of proceeds</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We estimate that the net proceeds from this offering will be approximately $6.4 million after deducting the placement agent fees and estimated offering expenses payable by us. We intend to use the net proceeds from this offering for working capital and general corporate purposes. See &#8220;<a href="#a_006">Use of Proceeds</a>&#8221; on page 13 for a more complete description of the intended use of proceeds from this offering.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>Reasonable best efforts offering</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have agreed to offer and sell the securities offered hereby to the purchasers through the placement agent. The placement agent is not required to buy or sell any specific number or dollar amount of the securities offered hereby, but will use their reasonable best efforts to solicit offers to purchase the securities offered by this prospectus. See &#8220;<a href="#a_016">Plan of Distribution</a>&#8221; on page 24 of this prospectus. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk Factors</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    investment in our securities involves a high degree of risk. See &#8220;<a href="#a_004">Risk Factors</a>&#8221; beginning on page 7
    of this prospectus and the other information included in this prospectus for a discussion of the risk factors you should carefully
    consider before deciding to invest in our securities.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nasdaq listing symbol</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our common stock is listed on The Nasdaq Capital Market under the symbol &#8220;CNSP.&#8221; There is no established trading market for the common warrants or pre-funded warrants and we do not expect a market to develop. In addition, we do not intend to apply for the listing of the common warrants or pre-funded warrants on any national securities exchange or other trading market. Without an active trading market, the liquidity of the common warrants and pre-funded warrants will be limited. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The number of shares of
common stock to be outstanding after this is based on 2,944,381 shares outstanding as of May 8, 2025, and excludes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">59,579 shares of common stock underlying outstanding
warrants at a weighted average exercise price of $465.88 per share;</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">270 shares of common stock underlying outstanding
options with a weighted average exercise price of $33,000.37 per share, which options vest over a three to four-year period;</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">119 shares of common stock underlying Restricted
Stock Units which vest over a four-year period and Performance Units which vest based on our performance against predefined share price
targets and the achievement of Positive Interim, Clinical Data as defined by the Board;</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">1,376 shares available for future issuance under
the CNS Pharmaceuticals, Inc. 2020 Stock Plan; and</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the shares of common stock issuable upon exercise
of the pre-funded warrants and the common warrants issued in this offering.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise indicated,
the information in this prospectus assumes no exercise of options or exercise of warrants or sale of pre-funded warrants in this offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information discussed
above is illustrative only and will adjust based on the actual public offering price and other terms of this offering determined at pricing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b><span id="a_004"></span>Risk
Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Investing in our securities
involves a high degree of risk. Before investing in our securities, you should consider carefully the risks and uncertainties discussed
under &#8220;Risk Factors&#8221; in our latest annual report on Form 10-K and subsequent quarterly reports on Form 10-Q and current reports
on Form 8-K. You should carefully consider each of the following risks, together with all other information set forth in this prospectus,
including the financial statements and the related notes, before making a decision to buy our securities. If any of the following risks
actually occurs, our business could be harmed. In that case, the trading price of our common stock could decline, and you may lose all
or part of your investment. </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to this Offering</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have in the past been unable to maintain
compliance with the listing requirements of The Nasdaq Capital Market, and any future failure to maintain compliance could subject our
common stock to be delisted from The Nasdaq Capital Market, which could have a material adverse effect on our financial condition and
could make it more difficult for you to sell your shares.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is listed
on The Nasdaq Capital Market, and we are therefore subject to its continued listing requirements, including requirements with respect
to the market value of publicly-held shares, market value of listed shares, minimum bid price per share, and minimum stockholder's equity,
among others, and requirements relating to board and committee independence. If we fail to satisfy one or more of the requirements, we
may be delisted from The Nasdaq Capital Market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During 2024, we were not in
compliance with the requirement to maintain a closing bid price of $1.00 per share (the &#8220;Minimum Bid Price Requirement&#8221;) pursuant
to Nasdaq Listing Rule 5550(a)(2), and we were not in compliance with the minimum $2,500,000 stockholders&#8217; equity requirement for
continued listing set forth in Listing Rule 5550(b) (the &#8220;Equity Requirement&#8221;). As of the date of the registration statement
of which this prospectus forms a part, we are in compliance with both requirements. However, with respect to the Equity Requirement, pursuant
to Nasdaq Listing Rule 5815(d)(4)(B), we are subject to a Mandatory Panel Monitor until September 10, 2025. If, within that monitoring
period, the Staff finds us again out of compliance with the Equity Requirement, notwithstanding Listing Rule 5810(c)(2), we will not be
permitted to provide the Staff with a plan of compliance with respect to that deficiency and Staff will not be permitted to grant additional
time for us to regain compliance with respect to that deficiency, nor will we be afforded an applicable cure or compliance period pursuant
to Listing Rule 5810(c)(3). With respect to the Minimum Bid Price Requirement, pursuant to Listing Rule 5815(d)(4)(B), we are subject
to a Mandatory Panel Monitor until March 31, 2026. If, within that monitoring period, the Staff finds us again out of compliance with
the Minimum Bid Price Requirement, notwithstanding Rule 5810(c)(2), we will not be permitted to provide the Staff with a plan of compliance
with respect to that deficiency and Staff will not be permitted to grant additional time for us to regain compliance with respect to that
deficiency, nor will we be afforded an applicable cure or compliance period pursuant to Rule 5810(c)(3). In either case described above,
the Staff will issue a Delist Determination Letter and we will have an opportunity to request a hearing. Our common stock may at that
time be delisted from Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There can be no assurance
that we will continue to meet the continued listing requirements of The Nasdaq Capital Market and could be subject to delisting at a future
time. Delisting from The Nasdaq Capital Market would adversely affect our ability to raise additional financing through the public or
private sale of equity securities, may significantly affect the ability of investors to trade our securities and may negatively affect
the value and liquidity of our common stock. Delisting also could have other negative results, including the potential loss of employee
confidence, the loss of institutional investors and general investors that will consider investing in our common stock, a reduction in
the number of market makers in our common stock, a reduction in the availability of information concerning the trading prices and volume
of our common stock, a reduction in the number of broker-dealers willing to execute trades in shares of our common stock or interest in
business development opportunities. Further, we would likely become a &#8220;penny stock&#8221;, which would make trading of our common
stock more difficult.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our management will have broad discretion
over the use of the net proceeds from this offering, you may not agree with how we use the proceeds, and the proceeds may not be invested
successfully.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management will have broad
discretion in the application of the net proceeds from this offering, and our stockholders will not have the opportunity as part of their
investment decision to assess whether the net proceeds are being used appropriately. Because of the number and variability of factors
that will determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their currently intended
use. The failure by our management to apply these funds effectively could harm our business. See &#8220;<a href="#a_006">Use of Proceeds</a>&#8221; on page 13 for a description of our proposed use of proceeds from this offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 12 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will require additional capital funding,
the receipt of which may impair the value of our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future capital requirements
depend on many factors, including our research, development, sales and marketing activities. We will need to raise additional capital
through public or private equity or debt offerings or through arrangements with strategic partners or other sources in order to continue
to develop our drug candidates. There can be no assurance that additional capital will be available when needed or on terms satisfactory
to us, if at all. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial
dilution and the new equity securities may have greater rights, preferences or privileges than our existing common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We do not intend to pay dividends in the
foreseeable future.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never paid cash dividends
on our common stock and currently do not plan to pay any cash dividends in the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Purchasers in this offering may experience
immediate and substantial dilution in net tangible book value.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The public offering price
per share of common stock and related common warrant and the public offering price of each pre-funded warrant and related common warrant
may be substantially higher than the pro forma as adjusted net tangible book value per share of our common stock after giving effect to
this offering. As a result of the dilution to investors purchasing securities in this offering, investors may receive significantly less
than the purchase price paid in this offering, if anything, in the event of the liquidation of our company. See the section entitled &#8220;<a href="#a_007">Dilution</a>&#8221;
below for a more detailed discussion of the dilution you may incur if you participate in this offering. To the extent shares are issued
under outstanding options and warrants at exercise prices lower than the public offering price of our common stock in this offering, you
will incur further dilution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Your ownership may be diluted if additional
capital stock is issued to raise capital, to finance acquisitions or in connection with strategic transactions.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will require additional,
substantial financing in order to complete our clinical trials. We intend to seek to raise additional funds for our operations, to finance
acquisitions or to develop strategic relationships by issuing equity or convertible debt securities in addition to the securities issued
in this offering, which would reduce the percentage ownership of our existing stockholders. Our board of directors has the authority,
without action or vote of the stockholders, to issue all or any part of our authorized but unissued shares of common or preferred stock.
Our articles of incorporation authorize us to issue up to 300,000,000 shares of common stock and 5,000,000 shares of preferred stock.
Future issuances of common or preferred stock would reduce your influence over matters on which stockholders vote and would be dilutive
to earnings per share. In addition, any newly issued preferred stock could have rights, preferences and privileges senior to those of
the common stock. Those rights, preferences and privileges could include, among other things, the establishment of dividends that must
be paid prior to declaring or paying dividends or other distributions to holders of our common stock or providing for preferential liquidation
rights. These rights, preferences and privileges could negatively affect the rights of holders of our common stock, and the right to convert
such preferred stock into shares of our common stock at a rate or price that would have a dilutive effect on the outstanding shares of
our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>There is no public market for the common
warrants or pre-funded warrants being offered in this offering.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no established public
trading market for the common warrants or pre-funded warrants being offered in this offering, and we do not expect a market to develop.
In addition, we do not intend to apply to list the common warrants or pre-funded warrants on any securities exchange or nationally recognized
trading system, including The Nasdaq Stock Market. Without an active market, the liquidity of the common warrants and pre-funded warrants
will be limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 13 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Holders of&#160;our&#160;common warrants
and pre-funded warrants will have no rights as a common stockholder until they acquire our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Until holders of our common
warrants and pre-funded warrants acquire shares of our common stock upon exercise of such common warrants or pre-funded warrants, the
holders will have no rights with respect to shares of our common stock issuable upon exercise of such common warrants or pre-funded warrants.
Upon exercise of the common warrants or pre-funded warrants, holders will be entitled to exercise the rights of a common stockholder only
as to matters for which the record date occurs after the exercise date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we do not maintain a current and effective
prospectus relating to the common stock issuable upon exercise of the common warrants and pre-funded warrants, public holders will only
be able to exercise such common warrants and pre-funded warrants on a &#8220;cashless basis.&#8221;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we do not maintain a current
and effective prospectus relating to the shares of common stock issuable upon exercise of the common warrants and pre-funded warrants
at the time that holders wish to exercise such warrants, they will only be able to exercise them on a &#8220;cashless basis,&#8221; and
under no circumstances would we be required to make any cash payments or net cash settle such warrants to the holders. As a result, the
number of shares of common stock that holders will receive upon exercise of the common warrants and pre-funded warrants will be fewer
than it would have been had such holders exercised their common warrants or pre-funded warrants for cash. We will do our best efforts
to maintain a current and effective prospectus relating to the shares of common stock issuable upon exercise of such warrants until the
expiration of such warrants. However, we cannot assure you that we will be able to do so. If we are unable to do so, the potential &#8220;upside&#8221;
of the holder&#8217;s investment in our company may be reduced.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The common warrants and pre-funded warrants
are speculative in nature.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The common warrants and pre-funded
warrants offered hereby do not confer any rights of common stock ownership on their holders, such as voting rights or the right to receive
dividends, but rather merely represent the right to acquire shares of common stock at a fixed price. Specifically, commencing on the date
of issuance, holders of the pre-funded warrants may acquire the common stock issuable upon exercise of such warrants at an exercise price
of $0.001 per share and holders of the common warrants may acquire the common stock issuable upon exercise of such warrants at an exercise
price per share equal to the public offering price of shares of common stock in this offering. Moreover, following this offering, the
market value of the pre-funded warrants and common warrants will be uncertain and there can be no assurance that the market value of such
warrants will equal or exceed their public offering price. There can be no assurance that the market price of the common stock will ever
equal or exceed the exercise price of the common warrants, and consequently, whether it will ever be profitable for holders of the common
warrants to exercise the common warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>This is a &#8220;best efforts&#8221; offering.
No minimum amount of securities is required to be sold, and we may not raise the amount of capital we believe is required for our business
plans, including our near-term business plans.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The placement agent has agreed
to use their reasonable best efforts to solicit offers to purchase the securities in this offering. The placement agent has no obligation
to buy any of the securities from us or to arrange for the purchase or sale of any specific number or dollar amount of the securities.
There is no required minimum number of securities that must be sold as a condition to completion of this offering. Because there is no
minimum offering amount required as a condition to the closing of this offering, the actual offering amount, placement agent fees and
proceeds to us are not presently determinable and may be substantially less than the maximum amounts set forth above. We may sell fewer
than all of the securities offered hereby, which may significantly reduce the amount of proceeds received by us, and investors in this
offering will not receive a refund in the event that we do not sell an amount of securities sufficient to support our continued operations,
including our near-term continued operations. Thus, we may not raise the amount of capital we believe is required for our operations and
may need to raise additional funds to complete such short-term operations. Such additional fundraises may not be available or available
on terms acceptable to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be required to repurchase the common
warrants, which may prevent or deter a third party from acquiring us.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The common warrants provide
that in the event of a &#8220;Fundamental Transaction&#8221; (as defined in the related warrant agreement, which generally includes any
merger with another entity, the sale, transfer or other disposition of all or substantially all of our assets to another entity, or the
acquisition by a person of more than 50% of our common stock), each common warrant holder will have the right at any time prior to the
consummation of the Fundamental Transaction to require us to repurchase the common warrant for a purchase price in cash equal to the Black-Scholes
value (as calculated under the warrant agreement) of the then remaining unexercised portion of such common warrant on the date of such
Fundamental Transaction, which may materially adversely affect our financial condition and/or results of operations and may prevent or
deter a third party from acquiring us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 14 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If our stock price fluctuates after the
offering, you could lose a significant part of your investment.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market price of our common
stock could be subject to wide fluctuations in response to, among other things, the risk factors described in this prospectus, and other
factors beyond our control, such as fluctuations in the valuation of companies perceived by investors to be comparable to us. Furthermore,
the stock markets have experienced price and volume fluctuations that have affected and continue to affect the market prices of equity
securities of many companies. These fluctuations often have been unrelated or disproportionate to the operating performance of those companies.
These broad market and industry fluctuations, as well as general economic, political, and market conditions, such as recessions, interest
rate changes or international currency fluctuations, may negatively affect the market price of our common stock. In the past, many companies
that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be
the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our
management&#8217;s attention from other business concerns, which could seriously harm our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>This offering may cause the trading price of our common stock
to decrease.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
price per share, together with the number of shares of common stock we issue if this offering is completed, may result in an immediate
decrease in the market price of our common stock. This decrease may continue after the completion of this offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have never paid dividends on our capital
stock, and we do not anticipate paying dividends in the foreseeable future.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We
have never paid dividends on any of our capital stock and currently intend to retain any future earnings to fund the growth of our business.
We may also enter into credit agreements or other borrowing arrangements in the future that will restrict our ability to declare or pay
cash dividends on our common stock. Any determination to pay dividends in the future will be at the discretion of our board of directors
and will depend on our financial condition, operating results, capital requirements, general business conditions and other factors that
our board of directors may deem relevant. As a result, capital appreciation, if any, of the securities will be the sole source of gain,
if any, for the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 15 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_005"></span>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus contains certain
forward-looking statements that involve substantial risks and uncertainties. All statements contained in this prospectus, other than statements
of historical facts, are forward-looking statements including statements regarding our strategy, future operations, future financial position,
future revenue, projected costs, prospects, plans, objectives of management and expected market growth. These statements involve known
and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially
different from any future results, performance or achievements expressed or implied by the forward-looking statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The words &#8220;anticipate&#8221;,
&#8220;believe&#8221;, &#8220;estimate&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;may&#8221;, &#8220;plan&#8221;, &#8220;predict&#8221;,
&#8220;project&#8221;, &#8220;target&#8221;, &#8220;potential&#8221;, &#8220;will&#8221;, &#8220;would&#8221;, &#8220;could&#8221;, &#8220;should&#8221;,
&#8220;continue&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements
contain these identifying words. These forward-looking statements include, among other things, statements about:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our ability to obtain additional funding to develop
our product candidates;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 110.25pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the need to obtain regulatory approval of our
product candidates;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 110.25pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the success of our clinical trials through all
phases of clinical development;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">compliance with obligations under intellectual
property licenses with third parties;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 110.25pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">any delays in regulatory review and approval
of product candidates in clinical development;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 110.25pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our ability to commercialize our product candidates;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 110.25pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">market acceptance of our product candidates;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 110.25pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">competition from existing products or new products
that may emerge;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 110.25pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">potential product liability claims;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 110.25pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our dependency on third-party manufacturers to
supply or manufacture our products;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 110.25pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our ability to establish or maintain collaborations,
licensing or other arrangements;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 110.25pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our ability and third parties&#8217; abilities
to protect intellectual property rights;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 110.25pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our ability to adequately support future growth;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 110.25pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our ability to attract and retain key personnel
to manage our business effectively;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 110.25pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our continued listing on Nasdaq; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 110.25pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our expectations regarding the use of proceeds
from this offering.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These forward-looking statements
are only predictions and we may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements,
so you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans,
intentions and expectations disclosed in the forward-looking statements we make. We have based these forward-looking statements largely
on our current expectations and projections about future events and trends that we believe may affect our business, financial condition
and operating results. We have included important factors in the cautionary statements included in this prospectus that could cause actual
future results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not
reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should read this prospectus with the understanding
that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking
statements whether as a result of new information, future events or otherwise, except as required by applicable law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b></b></span></p>

<!-- Field: Page; Sequence: 17 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b><span id="a_006"></span>Use
of Proceeds</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We estimate that the net proceeds
from the offering will be approximately $6.4 million, assuming we complete the maximum offering pursuant to this prospectus, after deducting
the placement agent fees and estimated offering expenses payable by us, and excluding the proceeds, if any, from the exercise of the common
warrants. However, because this is a &#8220;best efforts&#8221; offering and there is no minimum offering amount required as a condition
to the closing of this offering, the actual offering amount, the placement agent&#8217; fees and net proceeds to us are not presently
determinable and may be substantially less than the maximum amounts set forth on the cover page of this prospectus. As a result, we may
receive significantly less in net proceeds. Based on the assumed offering price set forth above, we estimate that our net proceeds from
the sale of 75%, 50%, and 25% of the securities offered in this offering would be approximately $4.8 million, $3.2 million, and $1.5 million,
respectively, after deducting the estimated placement agent fees and estimated offering expenses payable by us, and assuming no issuance
of any pre-funded warrants and assuming no exercise of the common warrants. The combined public offering price per share (or pre-funded
warrant) and common warrants will be fixed for the duration of this offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to use the net proceeds
from this offering for working capital and general corporate purposes. This represents our best estimate of the manner in which we will
use the net proceeds we receive from this offering based upon the current status of our business, but we have not reserved or allocated
amounts for specific purposes and we cannot specify with certainty how or when we will use any of the net proceeds. Amounts and timing
of our actual expenditures will depend on numerous factors. Our management will have broad discretion in applying the net proceeds from
this offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pending application of the
net proceeds as described above, we intend to invest the proceeds to us in investment-grade, interest-bearing securities such as money
market funds, certificates of deposit, or direct or guaranteed obligations of the U.S. government, or hold as cash. We cannot predict
whether the proceeds invested will yield a favorable, or any, return.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b><span id="a_007"></span>Dilution</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you invest in our securities
in this offering, your interest will be diluted immediately to the extent of the difference between the public offering price paid by
the purchasers of the shares of common stock (and pre-funded warrants) and related common warrants sold in this offering and the as adjusted
net tangible book value per shares of common stock after this offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2024, our
as reported net tangible book value was $6.2 million, or $4.37 per share of common stock. Net tangible book value per share represents
our total tangible assets, less our total liabilities, divided by the number of outstanding shares of our common stock. After giving effect
to 1,530,825 shares of common stock issued under the Company&#8217;s Sales Agreement for gross proceeds of $9.0 million subsequent to
December 31, 2024, our proforma net tangible book value was $15.2 million, or $5.16 per share of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dilution
                                            represents the difference between the amount per share paid by purchasers in this offering
                                            and the as adjusted net tangible book value per share of common stock after the offering.
                                            After giving effect to the sale of 6,250,000 shares of common stock and accompanying common
                                            warrants in this offering at an assumed offering price of $1.12 per share, which was the
                                            closing price of our common stock as reported on Nasdaq on May 8, 2025 and after deducting
                                            underwriting commissions and estimated offering expenses payable by us, but without adjusting
                                            for any other change in our net tangible book value subsequent to December 31, 2024, our
                                            pro forma as adjusted net tangible book value would have been $2.35 per share. This represents
                                            an immediate increase in net tangible book value on a reported basis of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
                                            and on a pro forma basis of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per
                                            share to our existing stockholders and immediate dilution of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per
                                            share to new investors purchasing securities at the proposed public offering price. The dilution
                                            figures assume no sale of pre-funded warrants, which, if sold, would reduce the number of
                                            shares of common stock that we are offering on a one-for-one basis, and excludes the proceeds,
                                            if any, from the exercise of any common warrants issued in this offering. The following table
                                            illustrates the dilution in net tangible book value per share to new investors as of December
                                            31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumed public offering price per share and accompanying common warrants</span></td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 11%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right; width: 11%">1.12</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historical net tangible book value per share at December 31, 2024 (pro forma - reflecting the sale of 1,530,825 shares of common stock under the Company&#8217;s Sales Agreement)</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.16</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase in net tangible book value per share to the existing stockholders on a pro forma basis attributable to --this offering.</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pro forma as adjusted net tangible book value per share after this offering</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.35</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution in net tangible book value per share to new investors on a pro forma as adjusted basis</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each
                                            $0.25 increase (decrease) in the assumed public offering price of $1.12 per share, would
                                            increase (decrease) our pro forma as adjusted net tangible book value per share to existing
                                            investors by $0.16, and would increase (decrease) dilution per share to new investors in
                                            this offering by $0.09, assuming that the number of shares offered by us, as set forth on
                                            the cover page of this prospectus, remains the same, and after deducting the estimated placement
                                            agent fees and estimated offering expenses payable by us. We may also increase or decrease
                                            the number of securities to be issued in this offering. Each increase (decrease) of&#8239;1
                                            million shares offered by us would increase (decrease) our pro forma as adjusted net tangible
                                            book value per share by $(0.13) and the dilution per share to new investors purchasing securities
                                            in this offering by $0.13 assuming that the assumed public offering price remains the same,
                                            and after deducting placement agent fees and estimated offering expenses payable by us. The
                                            information discussed above is illustrative only and will be adjusted based on the actual
                                            public offering price and other terms of this offering as determined between us and the placement
                                            agents at pricing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The number of shares of common
stock to be outstanding after this is based on 2,944,381 shares outstanding on a proforma basis as of December 31, 2024, and excludes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">59,579 shares of common stock underlying outstanding
warrants at a weighted average exercise price of $465.88 per share;</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">270 shares of common stock underlying outstanding
options with a weighted average exercise price of $33,000.37 per share, which options vest over a three to four-year period;</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">119 shares of common stock underlying Restricted
Stock Units which vest over a four-year period and Performance Units which vest based on our performance against predefined share price
targets and the achievement of Positive Interim, Clinical Data as defined by the Board;</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">1,376 shares available for future issuance under
the CNS Pharmaceuticals, Inc. 2020 Stock Plan; and</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the shares of common stock issuable upon exercise
of the pre-funded warrants and the common warrants issued in this offering.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
discussion and table above assume no exercise of the common warrants. To the extent that the warrants are exercised, you may experience
further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if
we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through
the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 19 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b><span id="a_008"></span>CAPITALIZATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets
forth our cash and cash equivalents and capitalization as of December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="width: 24px">&#160;</td>
    <td style="vertical-align: top; width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify; vertical-align: top">on an actual basis;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify; vertical-align: top">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify; vertical-align: top">on an as adjusted basis to give effect to 1,530,825 shares issued under the Company&#8217;s Sales Agreement subsequent to December 31, 2024;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify; vertical-align: top">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify; vertical-align: top">on a <i>pro forma</i> as adjusted basis to give further effect to the issuance
    and sale of 6,250,000 shares of our common stock and accompanying warrants in this offering at an assumed offering price of $1.12
    per share, which was the closing price of our common stock as reported on Nasdaq on May 8, 2025, after deducting the placement agent
    fees and estimated offering expenses payable by us, and assuming no sale of pre-funded warrants and no exercise of warrants.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our capitalization following
the closing of this offering will be adjusted based on the actual public offering price and other terms of this offering determined at
pricing. You should read this table in conjunction with &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and
Results of Operations&#8221; and our financial statements and related notes incorporated by reference in this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Actual</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><i>Pro Forma</i></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><i>Pro&#160;Forma</i><br/> As&#160;Adjusted</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 55%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">6,461,378</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">15,486,321</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">21,911,321</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Notes Payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">326,072</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">326,072</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">326,072</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Stockholders&#8217; equity (deficit):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt">Common stock, par value $0.001 per share: 300,000,000 shares authorized as
    of December 31, 2024; 1,413,556 shares issued and outstanding as of December 31, 2024; 2,944,381 shares issued and outstanding pro
    forma; 9,194,381 shares issued and outstanding pro&#160;forma as adjusted;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,414</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,944</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,194</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Additional&#160;paid-in&#160;capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90,599,901</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">99,623,313</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">106,042,063</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Accumulated deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(84,424,704</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(84,424,704</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(84,424,704</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total stockholders&#8217; equity (deficit)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,176,611</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">15,201,554</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">21,626,554</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total capitalization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">6,502,683</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">15,527,626</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">21,952,626</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A
                                            $0.25 increase or decrease in the assumed public offering price of $1.12 per share, which
                                            was the closing price of our common stock as reported on Nasdaq on May 8, 2025, would increase
                                            or decrease, respectively, our pro forma as adjusted cash and cash equivalents, additional
                                            paid-in capital, total stockholders&#8217; equity, and total capitalization by approximately
                                            $1,453,125, assuming the number of securities offered by us, as set forth on the cover page
                                            of this prospectus, remains the same, assuming no sale of any pre-funded warrants and no
                                            exercise of warrants, and after deducting underwriting discounts and commissions and estimated
                                            offering expenses payable by us. We may also increase or decrease the number of securities
                                            to be issued in this offering. An increase or decrease of 1 million in the number of shares
                                            of common stock and common warrants offered by us would increase or decrease, respectively,
                                            our pro forma as adjusted cash and cash equivalents, additional paid-in capital, total stockholders&#8217;
                                            equity, and total capitalization by $1,041,600, assuming that the assumed public offering
                                            price remains the same, assuming no sale of any pre-funded&#160;warrants and no exercise
                                            of warrants, and after deducting estimated placement agent fees and estimated offering expenses
                                            payable by us. The information discussed above is illustrative only and will be adjusted
                                            based on the actual public offering price and other terms of this offering as determined
                                            between us, the placement agent, and the investors at pricing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 20 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 15; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_012"></span>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
AND MANAGEMENT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets
forth information, as of May 9, 2025, regarding beneficial ownership of our common stock by:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each of our directors;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 38.25pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each of our named executive officers;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 38.25pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all directors and officers as a group; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 38.25pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each person, or group of affiliated persons, known by us to beneficially own more than five percent of our shares of common stock.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Beneficial ownership is determined
according to the rules of the SEC, and generally means that person has beneficial ownership of a security if he or she possesses sole
or shared voting or investment power of that security and includes options that are currently exercisable or exercisable within 60 days.
Each director or officer, as the case may be, has furnished us with information with respect to beneficial ownership. Except as otherwise
indicated, we believe that the beneficial owners of common stock listed below, based on the information each of them has given to us,
have sole investment and voting power with respect to their shares, except where community property laws may apply. Except as otherwise
noted below, the address for each person or entity listed in the table is c/o CNS Pharmaceuticals, Inc., 2100 West Loop South, Suite 900,
Houston, TX 77027.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt"><b>Name and address of beneficial owner</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Shares Beneficially<br/>
Owned</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Percentage of Class <sup>(1)</sup></b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">John Climaco</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">272 <sup>(2)(3)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Christopher S. Downs</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">114 <sup>(2)(4)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Sandra Silberman</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">12 <sup>(2)(5)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Faith Charles</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">26 <sup>(6)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Jerzy (George) Gumulka</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">78 <sup>(7)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Jeffry R. Keyes</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">33 <sup>(8)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Bettina Cockroft</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">20 <sup>(9)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Amy Mahery</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">15 <sup>(10)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 54%"><span style="font-size: 10pt"><b>Directors and Officers as a group (11 persons)</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 22%; text-align: center"><span style="font-size: 10pt"><b>570</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 22%; text-align: center"><span style="font-size: 10pt"><b>*</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Less than 1%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) Based on 2,944,381 shares of common stock
outstanding as of May 9, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) The restricted stock units granted to Mr.
Climaco, Mr. Downs and Dr. Silberman vest, in part, on the achievement of certain stock price and clinical trial milestones. For purposes
of the above table, we have assume that the foregoing milestones have not been achieved until such time as the board of directors makes
a determination that they have been achieved. See &#8220;Item 11. Executive Compensation &#8211; Executive Officer Compensation &#8211;
Narrative Disclosure to Summary Compensation Table &#8211; Long-Term Incentives&#8221; for details on the foregoing restricted stock unit
grants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) Includes warrants to purchase 134 shares
of common stock which are exercisable within 60 days of May 9, 2025, options to purchase 33 shares of common stock which are exercisable
within 60 days of May 9, 2025 4 restricted stock units which have vested by May 9, 2025, and 4 restricted stock units which will vest
within 60 days of May 9, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4) Includes warrants to purchase 54 shares
of common stock which are exercisable within 60 days of May 9, 2025, options to purchase 17 shares of common stock which are exercisable
within 60 days of May 9, 2025 2 restricted stock units which have vested by May 9, 2025, and 2 restricted stock units which will vest
within 60 days of May 9, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 21 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5) Includes options to purchase 10 shares
of common stock which are exercisable within 60 days of May 9, 2025 1 restricted stock unit which have vested by May 9, 2025, and 1 restricted
stock unit which will vest within 60 days of May 9, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6) Includes options to purchase 19 shares
of common stock which are exercisable within 60 days of May 9, 2025 and 7 restricted stock units which have vested by May 9, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(7) Includes warrants to purchase 28 shares
of common stock which are exercisable within 60 days of May 9, 2025, options to purchase 27 shares of common stock which are exercisable
within 60 days of May 9, 2025 and 7 restricted stock units which have vested by May 9, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8) Includes options to purchase 26 shares
of common stock which are exercisable within 60 days of May 9, 2025 and 7 restricted stock units which have vested by May 9, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(9) Includes options to purchase 13 shares
of common stock which are exercisable within 60 days of May 9, 2025 and 7 restricted stock units which have vested by May 9, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(10) Includes options to purchase 8 shares
of common stock which are exercisable within 60 days of May 9, 2025 and 7 restricted stock units which have vested by May 9, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 22 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b><span id="a_013"></span>Description
of Capital Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>The following summary of
the rights of our capital stock is not complete and is subject to and qualified in its entirety by reference to our amended and restated
articles of incorporation and bylaws, copies of which are filed as exhibits to the registration statement of which this prospectus forms
a part, which are incorporated by reference herein, and the applicable provisions of the Nevada Revised Statutes.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated articles
of incorporation authorize us to issue up to 300,000,000 shares of common stock and 5,000,000 shares of preferred stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shares of our common stock
have the following rights, preferences and privileges:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Voting</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each holder of common stock
is entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders. Any action at a meeting
at which a quorum is present will be decided by a majority of the voting power present in person or represented by proxy, except in the
case of any election of directors, which will be decided by a plurality of votes cast. There is no cumulative voting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dividends</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of our common stock
are entitled to receive dividends when, as and if declared by our board of directors out of funds legally available for payment, subject
to the rights of holders, if any, of any class of stock having preference over the common stock. Any decision to pay dividends on our
common stock will be at the discretion of our board of directors. Our board of directors may or may not determine to declare dividends
in the future. The board&#8217;s determination to issue dividends will depend upon our profitability and financial condition any contractual
restrictions, restrictions imposed by applicable law and the SEC, and other factors that our board of directors deems relevant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Liquidation Rights</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of a voluntary
or involuntary liquidation, dissolution or winding up of the Company, the holders of our common stock will be entitled to share ratably
on the basis of the number of shares held in any of the assets available for distribution after we have paid in full, or provided for
payment of, all of our debts and after the holders of all outstanding series of any class of stock have preference over the common stock,
if any, have received their liquidation preferences in full.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Other</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our issued and outstanding
shares of common stock are fully paid and nonassessable. Holders of shares of our common stock are not entitled to preemptive rights.
Shares of our common stock are not convertible into shares of any other class of capital stock, nor are they subject to any redemption
or sinking fund provisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Preferred Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are authorized to issue
up to 5,000,000 shares of preferred stock. We have no shares of preferred stock outstanding. Our amended and restated articles of incorporation
authorizes the board to issue these shares in one or more series, to determine the designations and the powers, preferences and relative,
participating, optional or other special rights and the qualifications, limitations and restrictions thereof, including the dividend rights,
conversion or exchange rights, voting rights (including the number of votes per share), redemption rights and terms, liquidation preferences,
sinking fund provisions and the number of shares constituting the series. Our board of directors could, without stockholder approval,
issue preferred stock with voting and other rights that could adversely affect the voting power and other rights of the holders of common
stock and which could have the effect of making it more difficult for a third party to acquire, or of discouraging a third party from
attempting to acquire, a majority of our outstanding voting stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 23 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Articles of Incorporation and Bylaw Provisions</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated articles
of incorporation and bylaws include a number of anti-takeover provisions that may have the effect of encouraging persons considering unsolicited
tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue non-negotiated takeover
attempts. These provisions include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Advance Notice Requirements</i>.
Our bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election
as directors or new business to be brought before meetings of stockholders. These procedures provide that notice of stockholder proposals
must be timely and given in writing to our corporate Secretary. Generally, to be timely, notice must be received at our principal executive
offices not fewer than 120 calendar days prior to the first anniversary date on which our notice of meeting and related proxy statement
were mailed to stockholders in connection with the previous year&#8217;s annual meeting of stockholders. The notice must contain the information
required by the bylaws, including information regarding the proposal and the proponent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Special Meetings of Stockholders</i>.
Our bylaws provide that special meetings of stockholders may be called at any time by only the Chairman of the Board, the Chief Executive
Officer, the President or the board of directors, or in their absence or disability, by any vice president.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Amendment of Bylaws</i>.
Our stockholders may amend any provisions of our bylaws by obtaining the affirmative vote of the holders of a majority of each class of
issued and outstanding shares of our voting securities, at a meeting called for the purpose of amending and/or restating our bylaws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Preferred Stock</i>. Our
amended and restated articles of incorporation authorizes our board of directors to create and issue rights entitling our stockholders
to purchase shares of our stock or other securities. The ability of our board to establish the rights and issue substantial amounts of
preferred stock without the need for stockholder approval may delay or deter a change in control of us. See &#8220;Preferred
Stock&#8221; above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Nevada Takeover Statute</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Nevada Revised Statutes
contain provisions governing the acquisition of a controlling interest in certain Nevada corporations. Nevada&#8217;s &#8220;acquisition
of controlling interest&#8221; statutes (NRS 78.378 through 78.3793, inclusive) contain provisions governing the acquisition of a controlling
interest in certain Nevada corporations. These &#8220;control share&#8221; laws provide generally that any person that acquires a &#8220;controlling
interest&#8221; in certain Nevada corporations may be denied voting rights, unless a majority of the disinterested stockholders of the
corporation elects to restore such voting rights. These laws will apply to us if we were to have 200 or more stockholders of record (at
least 100 of whom have addresses in Nevada appearing on our stock ledger) and do business in the State of Nevada directly or through an
affiliated corporation, unless our amended and restated articles of incorporation or bylaws in effect on the tenth day after the acquisition
of a controlling interest provide otherwise. These laws provide that a person acquires a &#8220;controlling interest&#8221; whenever a
person acquires shares of a subject corporation that, but for the application of these provisions of the NRS, would enable that person
to exercise (1) one-fifth or more, but less than one-third, (2) one-third or more, but less than a majority or (3) a majority or more,
of all of the voting power of the corporation in the election of directors. Once an acquirer crosses one of these thresholds, shares which
it acquired in the transaction taking it over the threshold and within the 90 days immediately preceding the date when the acquiring person
acquired or offered to acquire a controlling interest become &#8220;control shares&#8221; to which the voting restrictions described above
apply. These laws may have a chilling effect on certain transactions if our amended and restated articles of incorporation or amended
and restated bylaws are not amended to provide that these provisions do not apply to us or to an acquisition of a controlling interest,
or if our disinterested stockholders do not confer voting rights in the control shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nevada&#8217;s &#8220;combinations
with interested stockholders&#8221; statutes (NRS 78.411 through 78.444, inclusive) provide that specified types of business &#8220;combinations&#8221;
between certain Nevada corporations and any person deemed to be an &#8220;interested stockholder&#8221; of the corporation are prohibited
for two years after such person first becomes an &#8220;interested stockholder&#8221; unless the corporation&#8217;s board of directors
approves the combination (or the transaction by which such person becomes an &#8220;interested stockholder&#8221;) in advance, or unless
the combination is approved by the board of directors and 60% of the corporation&#8217;s voting power not beneficially owned by the interested
stockholder, its affiliates and associates. Furthermore, in the absence of prior approval certain restrictions may apply even after such
two-year period. For purposes of these statutes, an &#8220;interested stockholder&#8221; is any person who is (1) the beneficial owner,
directly or indirectly, of 10% or more of the voting power of the outstanding voting shares of the corporation, or (2) an affiliate or
associate of the corporation and at any time within the two previous years was the beneficial owner, directly or indirectly, of 10% or
more of the voting power of the then-outstanding shares of the corporation. The definition of the term &#8220;combination&#8221; is sufficiently
broad to cover most significant transactions between a corporation and an &#8220;interested stockholder&#8221;. These laws generally apply
to Nevada corporations with 200 or more stockholders of record. However, a Nevada corporation may elect in its articles of incorporation
not to be governed by these particular laws, but if such election is not made in the corporation&#8217;s original articles of incorporation,
the amendment (1) must be approved by the affirmative vote of the holders of stock representing a majority of the outstanding voting power
of the corporation not beneficially owned by interested stockholders or their affiliates and associates, and (2) is not effective until
18 months after the vote approving the amendment and does not apply to any combination with a person who first became an interested stockholder
on or before the effective date of the amendment. We have not made such an election in our original articles of incorporation or in our
amended and restated articles of incorporation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Limitations on Liability and Indemnification of Officers and Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated articles
of incorporation and bylaws limit the liability of our officers and directors and provide that we will indemnify our officers and directors,
in each case, to the fullest extent permitted by the Nevada Revised Statutes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Listing</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is listed
on The Nasdaq Capital Market under the symbol &#8220;CNSP.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Transfer Agent</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transfer agent for our
common stock is Continental Stock Transfer and Trust.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b><span id="a_014"></span>Description
of PRE-FUNDED WARRANTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>The following summary of
certain terms and provisions of pre-funded warrants that are being offered hereby is not complete and is subject to, and qualified in
its entirety by, the provisions of the pre-funded warrant, the form of which is filed as an exhibit to the registration statement of which
this prospectus forms a part.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Form</i></b>. The pre-funded
warrants will be issued as individual warrant agreements to the investors. You should review the form of pre-funded warrant, filed as
an exhibit to the registration statement of which this prospectus forms a part, for a complete description of the terms and conditions
applicable to the pre-funded warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Exercisability</i></b>.
The pre-funded warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise
notice accompanied by payment in full in immediately available funds for the number of shares of our common stock purchased upon such
exercise (except in the case of a cashless exercise as described below). A holder (together with its affiliates) may not exercise any
portion of the pre-funded warrant to the extent that the holder would own more than 4.99% (or, at the election of the holder, 9.99%) of
the outstanding common stock immediately after exercise, except that upon at least 61 days&#8217; prior notice from the holder to us,
the holder may increase the amount of ownership of outstanding stock after exercising the holder&#8217;s pre-funded warrants up to 9.99%
of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership
is determined in accordance with the terms of the pre-funded warrants. Purchasers of pre-funded warrants in this offering may also elect
prior to the issuance of the pre-funded warrants to have the initial exercise limitation set at 9.99% of our outstanding common stock.
No fractional shares of common stock will be issued in connection with the exercise of a pre-funded warrant. In lieu of fractional shares,
we will pay the holder an amount in cash equal to the fractional amount multiplied by the exercise price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Duration and Exercise
Price</i></b>. The exercise price per whole share of our common stock purchasable upon the exercise of the pre-funded warrants is $0.001
per share of common stock. The pre-funded warrants will be immediately exercisable and may be exercised at any time until the pre-funded
warrants are exercised in full. The exercise price of the pre-funded warrants is subject to appropriate adjustment in the event of certain
stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock and
also upon any distributions of assets, including cash, stock or other property to our stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Cashless Exercise</i></b>.
If, at any time after the holder&#8217;s purchase of pre-funded warrants, such holder exercises its pre-funded warrants and a registration
statement registering the issuance of the shares of common stock underlying the pre-funded warrants under the Securities Act is not then
effective or available (or a prospectus is not available for the resale of shares of common stock underlying the pre-funded warrants),
then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise
price, the holder shall instead receive upon such exercise (either in whole or in part) only the net number of shares of common stock
determined according to a formula set forth in the pre-funded warrants. Notwithstanding anything to the contrary, in the event we do not
have or maintain an effective registration statement, there are no circumstances that would require us to make any cash payments or net
cash settle the pre-funded warrants to the holders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Transferability</i></b>.
Subject to applicable laws, the pre-funded warrants may be offered for sale, sold, transferred or assigned at the option of the holder
upon surrender of the pre-funded warrant to us together with the appropriate instruments of transfer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Exchange Listing</i></b>.
We do not plan on applying to list the pre-funded warrants on Nasdaq, any other national securities exchange or any other nationally recognized
trading system.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Fundamental Transactions</i></b>.
In the event of a fundamental transaction, as described in the pre-funded warrants and generally including any reorganization, recapitalization
or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets,
our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding common stock, or any person
or group becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock, the holders of the pre-funded
warrants will be entitled to receive upon exercise of the pre-funded warrants the kind and amount of securities, cash or other property
that the holders would have received had they exercised the pre-funded warrants immediately prior to such fundamental transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Rights as a Stockholder</i></b>.
Except by virtue of such holder&#8217;s ownership of shares of our common stock, the holder of a pre-funded warrant does not have the
rights or privileges of a holder of our common stock, including any voting rights, until the holder exercises the pre-funded warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b></b></span></p>

<!-- Field: Page; Sequence: 26 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b><span id="a_015"></span>Description
of COMMON WARRANTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>The following summary of
certain terms and provisions of common warrants that are being offered hereby is not complete and is subject to, and qualified in its
entirety by, the provisions of the common warrant, the form of which is filed as an exhibit to the registration statement of which this
prospectus forms a part.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Series F Warrant</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Form</i></b>. The Series
F warrants will be issued as individual warrant agreements to the investors. You should review the form of Series F warrant, filed as
an exhibit to the registration statement of which this prospectus forms a part, for a complete description of the terms and conditions
applicable to the Series F warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Exercisability</i></b>.
The Series F warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise
notice accompanied by payment in full in immediately available funds for the number of shares of our common stock purchased upon such
exercise (except in the case of a cashless exercise as described below). A holder (together with its affiliates) may not exercise any
portion of the Series F warrant to the extent that the holder would own more than 4.99% (or, at the election of the holder, 9.99%) of
the outstanding common stock immediately after exercise, except that upon at least 61 days&#8217; prior notice from the holder to us,
the holder may increase the amount of ownership of outstanding stock after exercising the holder&#8217;s Series F warrants up to 9.99%
of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership
is determined in accordance with the terms of the Series F warrants. Purchasers of Series F warrants in this offering may also elect prior
to the issuance of the Series F warrants to have the initial exercise limitation set at 9.99% of our outstanding common stock. No fractional
shares of common stock will be issued in connection with the exercise of a Series F warrant. In lieu of fractional shares, we will pay
the holder an amount in cash equal to the fractional amount multiplied by the exercise price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Duration and Exercise
Price</i></b>. The assumed exercise price per whole share of our common stock purchasable upon the exercise of the Series F warrants
is $1.12 per share of common stock (or 100% of the assumed offering price per share and accompanying common warrants). The Series
F warrants will be exercisable beginning on the effective date of the Warrant Stockholder Approval, provided however, if the Pricing
Conditions are met, the Warrant Stockholder Approval will not be required and the Series F warrants will be exercisable on the Initial
Exercise Date. The Series F warrants will expire five years from the Initial Exercise Date or the Warrant Stockholder Approval, as applicable.
The exercise price of the Series F warrants is subject to appropriate adjustment in the event of certain stock dividends and distributions,
stock splits, stock combinations, reclassifications or similar events affecting our common stock and also upon any distributions of assets,
including cash, stock or other property to our stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Cashless Exercise</i></b>.
If, at any time after the holder&#8217;s purchase of Series F warrants, such holder exercises its Series F warrants and a registration
statement registering the issuance of the shares of common stock underlying the Series F warrants under the Securities Act is not then
effective or available (or a prospectus is not available for the resale of shares of common stock underlying the Series F warrants), then
in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price,
the holder shall instead receive upon such exercise (either in whole or in part) only the net number of shares of common stock determined
according to a formula set forth in the Series F warrants. Notwithstanding anything to the contrary, in the event we do not have or maintain
an effective registration statement, there are no circumstances that would require us to make any cash payments or net cash settle the
Series F warrants to the holders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Transferability</i></b>.
Subject to applicable laws, the Series F warrants may be offered for sale, sold, transferred or assigned at the option of the holder upon
surrender of the Series F warrant to us together with the appropriate instruments of transfer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Exchange Listing</i></b>.
We do not plan on applying to list the Series F warrants on the Nasdaq Capital Market, any other national securities exchange or any other
nationally recognized trading system.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 27 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Fundamental Transactions</i></b>.
In the event of a fundamental transaction, as described in the Series F warrants and generally including any reorganization, recapitalization
or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets,
our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding common stock, or any person
or group becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock, the holders of the Series
F warrants will be entitled to receive upon exercise of the Series F warrants the kind and amount of securities, cash or other property
that the holders would have received had they exercised the Series F warrants immediately prior to such fundamental transaction. In the
case of certain fundamental transactions affecting us, a holder of Series F warrants, upon exercise of such warrants after such fundamental
transaction, will have the right to receive, in lieu of shares of our common stock, the same amount and kind of securities, cash or property
that such holder would have been entitled to receive upon the occurrence of the fundamental transaction, had the Series F warrants been
exercised immediately prior to such fundamental transaction. In lieu of such consideration, a holder of Series F warrants may instead
elect to receive a cash payment based upon the Black-Scholes value of their Series F warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Rights as a Stockholder</i></b>.
Except by virtue of such holder&#8217;s ownership of shares of our common stock, the holder of a Series F warrant does not have the rights
or privileges of a holder of our common stock, including any voting rights, until the holder exercises the Series F warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 28 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_016"></span>PLAN OF DISTRIBUTION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">A.G.P./Alliance
Global Partners has agreed to act as our sole placement agent in connection with this offering subject to the terms and conditions of
the placement agency agreement dated __________, 2025. The placement agent is not purchasing or selling any of the securities offered
by this prospectus, nor are they required to arrange the purchase or sale of any specific number or dollar amount of securities, but have
agreed to use their reasonable best efforts to arrange for the sale of all of the securities offered hereby. We will enter into a securities
purchase agreement (the &#8220;purchase agreement&#8221;) directly with the investors who purchase our securities in this offering, at
the investors&#8217; option. Investors who do not enter into the purchase agreement shall rely solely on this prospectus in connection
with the purchase of our securities in this offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
expect this offering to be completed not later than one business day following the commencement of the offering and we will deliver the
securities being issued to each investor upon receipt of such investor&#8217;s funds for the purchase of the securities offered pursuant
to this prospectus and we will deliver all securities to be issued in connection with this offering delivery versus payment (DVP)/receipt
versus payment (RVP) upon receipt of investor funds received by us. We expect to deliver the securities being offered pursuant to this
prospectus on or about&#160;__________, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
have agreed to indemnify the placement agent against specified liabilities, including liabilities under the Securities Act, and to contribute
to payments the placement agent may be required to make in respect thereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Placement Agent Fees,
Commissions and Expenses</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">This
offering is being conducted on a reasonable best efforts basis and the placement agent has no obligation to buy any of the securities
from us or to arrange for the purchase or sale of any specific number or dollar amount of securities. Upon the closing of this offering,
we will pay the placement agent a cash transaction fee equal to 7.0% of the aggregate gross cash proceeds to us from the sale of the securities
in the offering. In addition, we will reimburse the placement agent for up to $85,000 for the placement agent&#8217; legal fees, and for
certain reasonable&#160;non-accountable&#160;fees and expenses not to exceed 1.0% of the aggregate gross cash proceeds to us from the
sale of the securities in the offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">The
following table shows the public offering price, placement agent fees and proceeds, before expenses, to us, assuming the sale of all the
shares of common stock we are offering and no exercise of any warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Per Share</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>and Accompanying</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Common Warrant</b></p></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Per Pre-Funded</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Warrant and Accompanying</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Common Warrant</b></p></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 61%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public offering price</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;&#160;</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement Agent fees</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds, before expenses, to us</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">We
estimate that the total expenses of the offering payable by us, excluding the total placement agent fees, will be approximately $200,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 29 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Lock-Up&#160;Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
directors and executive officers have entered into&#160;lock-up&#160;agreements. Under these agreements, these individuals have agreed,
subject to specified exceptions, not to sell or transfer any shares of common stock or securities convertible into, or exchangeable or
exercisable for, our shares of common stock during a period ending 90 days after the closing of this offering, without first obtaining
the written consent of the sole placement agent. Specifically, these individuals have agreed, in part, not to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">sell,
offer, contract or grant any option to sell (including any short sale), pledge, transfer, establish an open &#8220;put equivalent position&#8221;
within the meaning of Rule&#160;16a-l(h)&#160;under the Exchange Act;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">enter
into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of our
securities, whether any such transaction is to be settled by delivery of our shares of common stock, in cash or otherwise;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">make
any demand for or exercise any right with respect to the registration of any of our securities;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">publicly
disclose the intention to make any offer, sale, pledge or disposition, or to enter into any transaction, swap, hedge;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">or other
arrangement relating to any of our securities.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Notwithstanding
these limitations, these shares of common stock may be transferred under limited circumstances, including, without limitation, by gift,
will or intestate succession.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition, we have agreed that, subject to certain exceptions, we will not (i)&#160;conduct any issuances of our common stock for a period
of 60 days following closing of this offering or (ii)&#160;enter into a variable rate transaction (as defined in the purchase agreement)
for a period of 180 days following closing of this offering; provided that for the period commencing on the closing date of this offering
and ending on the 60th day following the closing of this offering, we will be permitted to make sales under our Sales Agreement with A.G.P./Alliance
Global Partners, if such sales are made at prices of not less than 150% of the combined offering price per share and accompanying warrant
in this offering, and for the period commencing on the 61st day following closing date of this offering and ending on the 180th day following
the closing of this offering, we will be permitted to make any sales under our Sales Agreement with A.G.P./Alliance Global Partners.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Regulation M</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">Each
placement agent may be deemed to be an underwriter within the meaning of Section&#160;2(a)(11) of the Securities Act, and any commissions
received by it and any profit realized on the resale of the shares sold by it while acting as principal might be deemed to be underwriting
discounts or commissions under the Securities Act. As an underwriter, each placement agent would be required to comply with the requirements
of the Securities Act and the Exchange Act, including, without limitation, Rule 415(a)(4) under the Securities Act and Rule&#160;10b-5&#160;and
Regulation M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of shares by the placement
agent acting as principal. Under these rules and regulations, the placement agent:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">may not
engage in any stabilization activity in connection with our securities; and</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">may not
bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than as permitted
under the Exchange Act, until it has completed its participation in the distribution.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Listing</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">Our
common stock is listed on The Nasdaq Capital Market under the symbol &#8220;CNSP.&#8221; There is no established public market for the
common warrants or pre-funded warrants, and we do not expect a market to develop. In addition, we do not intend to apply for listing of
the common warrants or pre-funded warrants on any national securities exchange.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"></p>

<!-- Field: Page; Sequence: 30 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Discretionary Accounts</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">The
placement agent does not intend to confirm sales of the securities offered hereby to any accounts over which they have discretionary authority.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Other Relationships</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
October 2023, we completed the warrant inducement transaction. We engaged A.G.P./Alliance Global Partners (&#8220;AGP") to act as
our financial advisor in connection with the transaction and paid A.G.P./Alliance Global Partners a fee of $145,000. In December 2023,
we engaged A.G.P./Alliance Global Partners to act as our lead placement agent in connection with a registered offering and paid A.G.P./Alliance
Global Partners a fee of $279,222.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
January 2024, we completed a public offering of our securities. In connection therewith, we entered into a placement agency agreement
with&#160;AGP and Maxim Group LLC (&#8220;Maxim&#8221; and collectively with AGP, the &#8220;January Placement Agents&#8221;) pursuant
to which we agreed to pay the January Placement Agents &#160;an aggregate fee equal to 7% of the gross proceeds received by us from the
sale of the securities in the transaction. We also agreed to&#160;reimburse the January Placement Agents for (i) up to $75,000 for the
placement agents&#8217; legal fees, (ii) up to $25,000 of the aggregate gross proceeds of the offering for certain reasonable&#160;non-accountable&#160;fees
and expenses and (iii)&#160;closing costs (including the reimbursement of the reasonable out-of-pocket cost of the escrow agent or clearing
agent) in an amount up to $10,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
mid June 2024, we completed a registered direct offering and concurrent private placement. In connection therewith, we entered into a
financial advisory agreement with&#160;AGP pursuant to which we agreed to pay AGP an aggregate fee equal to 6.5% of the aggregate gross
proceeds received by us from the sale of the securities in the offering and private placement. We also agreed to reimburse AGP for up
to $80,000 in legal fees and expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
late June 2024, we completed a second registered direct offering and concurrent private placement that month. In connection therewith,
we entered into a financial advisory agreement with&#160;AGP pursuant to which we agreed to pay AGP an aggregate fee equal to 6.5% of
the aggregate gross proceeds received by us from the sale of the securities in the offering and private placement. We also agreed to reimburse
AGP for up to $80,000 in legal fees and expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
July 2024, we completed a registered direct offering and concurrent private placement. In connection therewith, we entered into a financial
advisory agreement with&#160;AGP pursuant to which we agreed to pay AGP an aggregate fee equal to 6.5% of the aggregate gross proceeds
received by us from the sale of the securities in the offering and private placement. We also agreed to reimburse AGP for up to $65,000
in legal fees and expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
July 26, 2024, we entered into a sales agreement (the Sales Agreement) with AGP. Pursuant to the terms of the Sales Agreement, the Company
may sell from time to time through AGP, as sales agent or principal, shares of the Company&#8217;s common stock. The Company will pay
a commission to AGP of 3.0% of the gross proceeds of the sale of the shares of common stock sold under the Sales Agreement and reimburse
AGP for certain expenses. The Company has also provided AGP with customary indemnification rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
October 2024, we completed a registered direct offering. In connection therewith, we entered into a financial advisory agreement with&#160;AGP
pursuant to which we agreed to pay AGP an aggregate fee equal to 6.5% of the aggregate gross proceeds received by us from the sale of
the securities in the offering and private placement. We also agreed to reimburse AGP for up to $60,000 in legal fees, non-accountable
expenses of $20,000, and up to $10,000 in out-of-pocket closing costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 31 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
placement agent and certain of its affiliates are full service financial institutions engaged in various activities, which may include
securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment,
hedging, financing and brokerage activities. The placement agent and certain of its affiliates may in the future perform various commercial
and investment banking and financial advisory services for us and our affiliates, for which they will receive customary fees and expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
the ordinary course of their various business activities, the placement agent and certain of its affiliates may make or hold a broad array
of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank
loans) for their own account and for the accounts of their customers, and such investment and securities activities may involve securities
and/or instruments issued by us and our affiliates. If the placement agent or its affiliates have a lending relationship with us, they
routinely hedge their credit exposure to us consistent with their customary risk management policies. The placement agent and its affiliates
may hedge such exposure by entering into transactions that consist of either the purchase of credit default swaps or the creation of short
positions in our securities or the securities of our affiliates, including potentially the common stock offered hereby. Any such short
positions could adversely affect future trading prices of the common stock offered hereby. The placement agent and certain of its affiliates
may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research
views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long and/or short
positions in such securities and instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_017"></span>LEGAL MATTERS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The validity of the securities
offered hereby will be passed upon for us by ArentFox Schiff LLP, Washington, DC. The placement agent is being represented by Sullivan
&amp; Worcester LLP, New York, New York, in connection with this offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_018"></span>EXPERTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The financial statements of
CNS Pharmaceuticals, Inc. incorporated in this prospectus by reference to the Annual Report on Form 10-K for the year ended December 31,
2024 have been so incorporated in reliance on the report which contains an explanatory paragraph regarding the Company&#8217;s ability
to continue as a going concern of MaloneBailey, LLP, an independent registered public accounting firm, given on the authority of said
firm as experts in auditing and accounting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_019"></span>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SEC allows us to &#8220;incorporate
by reference&#8221; information from other documents that we file with it, which means that we can disclose important information to you
by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus. Information
in this prospectus supersedes information incorporated by reference that we filed with the SEC prior to the date of this prospectus. We
incorporate by reference into this prospectus and the registration statement of which this prospectus is a part the information or documents
listed below that we have filed with the SEC:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top">
<td style="width: 48px"/><td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our Annual Report on <a href="https://www.sec.gov/Archives/edgar/data/1729427/000168316825002139/cns_i10k-123124.htm">Form 10-K</a> for the year ended
December 31, 2024, filed on March 31, 2025;</span></td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                            <tr style="vertical-align: top">
<td>&#160;</td><td><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Our Annual Report on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1729427/000168316825002998/cns_10ka1-123124.htm">Form 10-K/A</a> for the year ended December 31, 2024, filed on April 30, 2025;</td></tr>
                                                            <tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                            </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top">
<td style="width: 48px"/><td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our Current Reports on Form 8-K filed on <a href="https://www.sec.gov/Archives/edgar/data/1729427/000168316825000077/cns_8k.htm">January 3, 2025</a>; <a href="https://www.sec.gov/Archives/edgar/data/1729427/000168316825001174/cns_8k.htm">February 21, 2025</a>; <a href="https://www.sec.gov/Archives/edgar/data/1729427/000168316825001754/cns_8k.htm">March 20, 2025</a>; and <a href="https://www.sec.gov/Archives/edgar/data/1729427/000168316825002140/cns_8k.htm">March 31, 2025</a>; in each case to the extent the information in such reports is filed and
not furnished; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top">
<td style="width: 48px"/><td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the description of our common stock contained
in our registration statement on <a href="https://www.sec.gov/Archives/edgar/data/1729427/000168316819003435/cns_8a12b-11052019.htm">Form 8-A</a> filed with the SEC on November 5, 2019, including any amendments or reports filed for the purposes
of updating this description, including any exhibits to our Annual Report on Form 10-K.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, all documents
filed by us with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after (i) the date of the initial registration statement
and prior to effectiveness of the registration statement, and (ii) the date of this prospectus and before the termination or completion
of any offering hereunder, shall be deemed to be incorporated by reference into this prospectus from the respective dates of filing of
such documents, except that we do not incorporate any document or portion of a document that is &#8220;furnished&#8221; to the SEC, but
not deemed &#8220;filed.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will furnish without charge
to you, on written or oral request, a copy of any or all of the documents incorporated by reference in this prospectus, including exhibits
to these documents. You should direct any requests for documents to CNS Pharmaceuticals, Inc., Attn: Corporate Secretary, 2100 West Loop
South, Suite 900, Houston, TX 77027.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You also may access these
filings on our website at www.cnspharma.com. We do not incorporate the information on our website into this prospectus or any supplement
to this prospectus and you should not consider any information on, or that can be accessed through, our website as part of this prospectus
or any supplement to this prospectus (other than those filings with the SEC that we specifically incorporate by reference into this prospectus
or any supplement to this prospectus).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any statement contained in
a document incorporated or deemed to be incorporated by reference in this prospectus will be deemed modified, superseded or replaced for
purposes of this prospectus to the extent that a statement contained in this prospectus modifies, supersedes or replaces such statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<!-- Field: Page; Sequence: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_020"></span>WHERE YOU CAN FIND MORE INFORMATION </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have filed with the SEC
a registration statement on Form S-1 under the Securities Act for the securities being offered by this prospectus. This prospectus, which
is part of the registration statement, does not contain all of the information included in the registration statement and the exhibits.
For further information about us and the securities offered by this prospectus, you should refer to the registration statement and its
exhibits. References in this prospectus to any of our contracts or other documents are not necessarily complete, and you should refer
to the exhibits attached to the registration statement for copies of the actual contract or document. SEC filings are also available to
the public at the SEC&#8217;s website at <i>www.sec.gov</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the reporting
and information requirements of the Exchange Act and, as a result, we file periodic and current reports, proxy statements and other information
with the SEC. We make our periodic reports and other information filed with or furnished to the SEC, available, free of charge, through
our website as soon as reasonably practicable after those reports and other information are filed with or furnished to the SEC. Additionally,
these periodic reports, proxy statements and other information are available for inspection and copying at the public reference room and
website of the SEC referred to above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 34 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-size: 12pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>Up to 6,250,000
Shares of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>Up to 6,250,000
Pre-Funded Warrants to Purchase up to 6,250,000 Shares of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>Up to 6,250,000
Series F Common Warrants to Purchase up to 6,250,000 Shares of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>Up to 6,250,000
Shares of Common Stock Underlying such Pre-Funded Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>Up to 6,250,000
Shares of Common Stock Underlying such Series F Common Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 16pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CNS Pharmaceuticals, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>Sole Placement Agent</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 100%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 16pt"><b>A.G.P.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PROSPECTUS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>________________</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 35 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INFORMATION NOT REQUIRED IN PROSPECTUS </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item&#160;13. Other Expenses of Issuance and Distribution.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
the estimated costs and expenses to be incurred in connection with the issuance and distribution of the securities of CNS Pharmaceuticals,
Inc. (the &#8220;Registrant&#8221;) which are registered under this Registration Statement on Form S-1 (this &#8220;Registration Statement&#8221;),
other than placement agent fees. All amounts are estimates except the Securities and Exchange Commission registration fee and the Financial
Industry Regulatory Authority, Inc. filing fee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following expenses will
be borne solely by the Registrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount&#160;to&#160;be<br/> Paid</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: left">SEC Registration fee</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,143.40</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Financial Industry Regulatory Authority, Inc. filing fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,600.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Legal fees and expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150,000.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounting fees and expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,000.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Transfer Agent&#8217;s fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Miscellaneous fees and expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,000.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">204,743.40</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item&#160;14. Indemnification of Directors and Officers. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 78.138 of the Nevada
Revised Statute provides that a director or officer is not individually liable to the corporation or its stockholders or creditors for
any damages as a result of any act or failure to act in his capacity as a director or officer unless it is proven that (1) his act or
failure to act constituted a breach of his fiduciary duties as a director or officer and (2) his breach of those duties involved intentional
misconduct, fraud or a knowing violation of law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This provision is intended
to afford directors and officers protection against and to limit their potential liability for monetary damages resulting from suits alleging
a breach of the duty of care by a director or officer. As a consequence of this provision, stockholders of our company will be unable
to recover monetary damages against directors or officers for action taken by them that may constitute negligence or gross negligence
in performance of their duties unless such conduct falls within one of the foregoing exceptions. The provision, however, does not alter
the applicable standards governing a director&#8217;s or officer&#8217;s fiduciary duty and does not eliminate or limit the right of our
company or any stockholder to obtain an injunction or any other type of non-monetary relief in the event of a breach of fiduciary duty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Registrant&#8217;s Articles
of Incorporation, as amended, and amended and restated bylaws provide for indemnification of directors, officers, employees or agents
of the Registrant to the fullest extent permitted by Nevada law (as amended from time to time). Section 78.7502 of the Nevada Revised
Statute provides that such indemnification may only be provided if the person acted in good faith and in a manner he or she reasonably
believed to be in, or not opposed to, the best interest of the Registrant and, with respect to any criminal action or proceeding, had
no reasonable cause to behave his conduct was unlawful.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item&#160;15. Recent Sales of Unregistered Securities. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as set forth below,
in the three years preceding the filing of this Registration Statement, the Registrant has not issued any securities that were not registered
under the Securities Act (all share and per share numbers are reflected on a post-split basis for all periods presented):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 36; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2023, the Registrant
entered into a warrant exercise inducement offer letter with a holder of certain existing warrants to purchase common stock (the &#8220;Existing
Warrants&#8221;) to receive new warrants (the &#8220;Inducement Warrants&#8221;) to purchase up to a number of shares of common stock
equal to 200% of the number of warrant shares issued pursuant to the exercise of such Existing Warrants to purchase shares of common stock,
pursuant to which the warrant holder agreed to exercise for cash its Existing Warrants to purchase up to 752 shares of the Registrant&#8217;s
common stock,&#160;at $3,200.00 per share, in exchange for the Registrant&#8217;s agreement to issue Inducement Warrants to purchase up
to 1,503 shares of the Registrant&#8217;s common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 29, 2024, the Registrant
entered into a warrant amendment agreement pursuant to which it agreed, subject to stockholder approval, to amend the Inducement Warrants
to purchase up to an aggregate of 1,503 shares of common stock at an exercise price of $3,200.00 per share and a termination date of October
16, 2028, so that the amended warrants will have a reduced exercise price of $705.00 per share and a new termination date of February
1, 2029. The requisite stockholder approval for the amendments was obtained at the Registrant&#8217;s 2024 Annual Meeting of Stockholders
held on April 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 14, 2024, the Registrant
issued to investors unregistered warrants to purchase up to an aggregate of 7,320 shares of common stock (the Series C Common Warrants).
Subject to certain ownership limitations, each of the Series C Common Warrants was immediately exercisable, has an exercise price of $181.00
per share, and will expire five years from the date of issuance (issued June 17, 2024).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 26, 2024, the Registrant
issued to investors unregistered warrants to purchase up to an aggregate of 11,360 shares of common stock (the Series D Common Warrants).
Subject to certain ownership limitations, each of the Series D Common Warrants was immediately exercisable, has an exercise price of $122.50
per share, and will expire five years from the date of issuance (issued June 27, 2024).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 5, 2024, the Registrant
issued to investors unregistered warrants to purchase up to an aggregate of 28,500 shares of common stock (the Series E Common Warrants).
Subject to certain ownership limitations, each of the Series E Common Warrants was immediately exercisable, has an exercise price of $63.00
per share, and will expire five years from the date of issuance (issued July 5, 2024).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 29, 2024, the Registrant
entered into Exclusive License Agreement and Stock Purchase Agreement (collectively, the &#8220;Cortice Agreements&#8221;) with Cortice
Biosciences, Inc. (&#8220;Cortice&#8221;) pursuant to which Cortice granted the Company an exclusive license to the intellectual property
rights related to certain patents around the compound TPI 287 in the United States, Canada, Mexico and Japan. Pursuant to the Cortice
Agreements, the Company agreed to issue Cortice 11,468 shares of Company common stock upon the closing of the transaction, and 867 shares
of Company common stock upon the receipt of shareholder approval of such issuance as required by the rules of the Nasdaq Stock Market.
The Company also agreed to make milestone payments to Cortice in either cash or shares of Company common stock (at Cortice&#8217;s option)
upon: (i) meeting the primary endpoint a pivotal trial for a licensed product &#8211; either $15.0 million or 8,223 shares of Company
common stock; (ii) FDA acceptance of an New Drug Application for a licensed product &#8211; either $30.0 million or 16,446 shares of Company
common stock; (iii) the first commercial sale in the United States of a licensed product &#8211; either $45.0 million or 24,668 shares
of Company common stock; and (iv) the first commercial sale in Japan of a licensed product &#8211; either $10.0 million or 4,112 shares
of Company common stock. The Company&#8217;s obligation to pay the above milestones in Company common stock is subject to the receipt
of shareholder approval as required by the rules of the Nasdaq Stock Market. The Company also agreed to pay Cortice royalties on sales
of licensed products of between 3.0%-7.5%. Finally, to the extent Cortice is required to pay any milestone payments to the original holder
of the intellectual property rights licensed, the Company has agreed to make such payments to Cortice.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of the securities
above were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act or Regulation D promulgated
thereunder. The issuance of the Inducement Warrants was made in reliance on the exemption provided by Section 3(a)(9) of the Securities
Act.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 37 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 16. Exhibits and Financial Statement Schedules.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (a) <b><i>Exhibits</i></b>:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom; width: 8%"><b>Exhibit<br/>
    Number</b></td>
    <td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom; width: 2%"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom; width: 90%"><b>Description of Document</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1729427/000168316825002548/cns_ex0101.htm">Form of Placement Agency Agreement</a> (incorporated by reference to Exhibit
    1.1 to the Company&#8217;s Form S-1  filed with the Commission on April 14, 2025)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1729427/000168316818001028/filename3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Articles of Incorporation of CNS Pharmaceuticals, Inc.</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference Exhibit 2.1 to the Company&#8217;s Form 1-A file no. 024-10855)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/1729427/000168316822008064/cns_ex0301.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to the Amended and Restated Articles of Incorporation of CNS Pharmaceuticals, Inc., filed with the Secretary of State of the State of Nevada</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Commission on November 28, 2022)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1729427/000168316824002961/cns_0301.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to the Amended and Restated Articles of Incorporation of CNS Pharmaceuticals, Inc., filed with the Secretary of State of the State of Nevada</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Commission on May 3, 2024)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1729427/000168316824003998/cns_ex0301.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to the Amended and Restated Articles of Incorporation of CNS Pharmaceuticals, Inc., filed with the Secretary of State of the State of Nevada</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Commission on June 5, 2024)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1729427/000168316818001028/filename4.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Bylaws of CNS Pharmaceuticals, Inc.</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 3.1 to the Company&#8217;s Form 8-K filed August 15, 2023)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/1729427/000168316825002139/cns_ex0401.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Securities of CNS Pharmaceuticals, Inc.</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 4.1 to the Annual Report on Form 10-K filed with the Commission on March 31, 2025)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1729427/000168316822000120/cnspharma_ex0401.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant issued in January 2022 offering</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the Commission on January 6, 2022)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/1729427/000168316822007789/cns_ex0408.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Common Warrant issued in November 2023 offering</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 4.8 to the Company&#8217;s Form S-1 file no. 333-267975)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/1729427/000168316822007789/cns_ex0409.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Placement Agent Warrant issued in November 2023 offering</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 4.9 to the Company&#8217;s Form S-1 file no. 333-267975)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1729427/000168316822000120/cnspharma_ex0401.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Inducement Warrant issued in October 2023</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the Commission on October 17, 2023)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/1729427/000168316824000660/cns_ex0401.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series A Common Warrant issued January 2024</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the Commission on February 2, 2024)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/1729427/000168316824000660/cns_ex0402.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series B Common Warrant issued January 2024</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K filed with the Commission on February 2, 2024)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/1729427/000168316824000660/cns_ex0403.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Pre-Funded Warrant issued January 2024</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 4.3 to the Current Report on Form 8-K filed with the Commission on February 2, 2024)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1729427/000168316824004253/cns_ex0401.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant issued June 14 2024</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K filed with the Commission on June 14, 2024)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>

<tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1729427/000168316824004253/cns_ex0402.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Pre-Funded Warrant issued June 14 2024</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the Commission on June 14, 2024)</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 38 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/1729427/000168316824004501/cns_ex0401.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant issued June 26 2024</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the Commission on June 26, 2024)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1729427/000168316824004667/cns_ex0401.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant issued July 3 2024</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the Commission on July 3, 2024)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1729427/000168316824007371/cns_ex0401.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Pre-Funded Warrant issued October 23 2024</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the Commission on October 24, 2024)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1729427/000168316825002548/cns_ex0413.htm">Form of Series F Warrant</a> (incorporated by reference to Exhibit
    4.13 to the Company&#8217;s Form S-1  filed with the Commission on April 14, 2025)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1729427/000168316825002548/cns_ex0414.htm">Form of Pre-Funded Warrant</a> (incorporated by reference to Exhibit
    4.14 to the Company&#8217;s Form S-1  filed with the Commission on April 14, 2025)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1729427/000168316825002548/cns_ex0501.htm">Opinion of ArentFox Schiff, LLP</a> (incorporated by reference to Exhibit
    5.1 to the Company&#8217;s Form S-1  filed with the Commission on April 14, 2025)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1729427/000168316818001713/cns_a1-ex0601.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended And Restated Patent License Agreement effective as of December 28, 2017 between CNS Pharmaceuticals, Inc. and Houston Pharmaceuticals, Inc. </span></a><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 6.1 to the Company&#8217;s Form 1-A file no. 024-10855)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1729427/000168316818001713/cns_a1-ex0602.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaboration and Asset Purchase Agreement between CNS Pharmaceuticals, Inc. and Reata Pharmaceuticals, Inc. dated November 21, 2017</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 6.2 to the Company&#8217;s Form 1-A file no. 024-10855)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3 **</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1729427/000168316818001713/cns_a1-ex0603.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017 Stock Plan of CNS Pharmaceuticals, Inc. </span></a><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 6.3 to the Company&#8217;s Form 1-A file no. 024-10855)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4 **</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1729427/000168316818001713/cns_a1-ex0604.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement between CNS Pharmaceuticals, Inc. and John M. Climaco dated September 1, 2017</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 6.4 to the Company&#8217;s Form 1-A file no. 024-10855)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1729427/000168316818002664/cns_a1-ex0606.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sublicense Agreement between CNS Pharmaceuticals, Inc. and WPD Pharmaceuticals, Inc. dated August 30, 2018</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 6.6 to the Company&#8217;s Form 1-A Amendment file no. 024-10855)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1729427/000168316818002664/cns_a1-ex0607.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sublicense Agreement between CNS Pharmaceuticals, Inc. and Animal Life Sciences, LLC. dated August 31, 2018</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 6.7 to the Company&#8217;s Form 1-A Amendment file no. 024-10855)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7 **</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1729427/000168316819002206/cns_ex1008.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Letter between CNS Pharmaceuticals, Inc. and Donald Picker</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 10.8 to the Company&#8217;s Form S-1 Amendment file no. 333-232443)</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8 **</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1729427/000168316819002206/cns_ex1009.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Letter between CNS Pharmaceuticals, Inc. and Sandra Silberman</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 10.9 to the Company&#8217;s Form S-1 Amendment file no. 333-232443)</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9 **</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1729427/000168316819003197/cns_ex1010.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement between CNS Pharmaceuticals, Inc. and Christopher Downs</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 10.10 to the Company&#8217;s Form S-1 Amendment file no. 333-232443)</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10 **</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1729427/000168316824002961/cns_1001.htm">2020 Stock Plan of CNS Pharmaceuticals, Inc. (as amended)</a> (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Commission on May 3, 2024)</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11**</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1729427/000168316820003043/cns_ex9901.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Employment Agreement between CNS Pharmaceuticals, Inc. and John Climaco dated September 1, 2020</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 99.1 to the Company&#8217;s Form 8-K filed September 4, 2020)</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1729427/000168316822005637/cns_ex1001.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Employee Director Compensation Policy effective July 15, 2021</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 10-Q filed with the Commission on August 12, 2022)</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1729427/000168316822007789/cns_ex1021.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Placement Agent Agreement in November 2023 offering</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 10.21 to the Company&#8217;s Form S-1 file no. 333-267975)</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>

<tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1729427/000168316822000120/cnspharma_ex0401.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Securities Purchase Agreement in January 2024</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Commission on February 2, 2024)</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 39 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="vertical-align: top; width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/1729427/000168316822000120/cnspharma_ex0401.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Amendment to Common Stock Warrants </span></a><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Commission on February 2, 2024)</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1729427/000168316822000120/cnspharma_ex0401.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Securities Purchase Agreement in June 14 2024</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">offering (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Commission on June 14, 2024)</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1729427/000168316824004253/cns_ex1002.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Advisory Agreement between CNS Pharmaceuticals, Inc. and A.G.P./Alliance Global Partners</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Commission on June 14, 2024)</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1729427/000168316822000120/cnspharma_ex0401.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Securities Purchase Agreement in June 26, 2024</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">offering (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Commission on June 26, 2024)</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1729427/000168316824004501/cns_ex1002.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Advisory Agreement between CNS Pharmaceuticals, Inc. and A.G.P./Alliance Global Partners</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Commission on June 26, 2024)</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1729427/000168316822000120/cnspharma_ex0401.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Securities Purchase Agreement in July 3, 2024</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">offering (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Commission on July 3, 2024)</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1729427/000168316824004667/cns_ex1002.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Advisory Agreement between CNS Pharmaceuticals, Inc. and A.G.P./Alliance Global Partners</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Commission on July 3, 2024)</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1729427/000168316824005070/cns_ex0101.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales Agreement, dated July 26, 2024, by and between CNS Pharmaceuticals, Inc. and A.G.P./Alliance Global Partners</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 1.1 to the Current Report on Form 8-K filed with the Commission on July 26, 2024)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1729427/000168316824005070/cns_ex1001.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Waiver and Consent</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Commission on July 26, 2024)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1729427/000168316824005118/cns_ex1001.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exclusive License Agreement between CNS Pharmaceuticals, Inc. and Cortice Biosciences, Inc.</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Commission on July 30, 2024)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1729427/000168316824005118/cns_ex1002.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Purchase Agreement between CNS Pharmaceuticals, Inc. and Cortice Biosciences, Inc.</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Commission on July 30, 2024)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1729427/000168316822000120/cnspharma_ex0401.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Securities Purchase Agreement in October 23 2024</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">offering (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Commission on October 24, 2024)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1729427/000168316824007371/cns_ex0101.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement Agency Agreement between CNS Pharmaceuticals, Inc. and A.G.P./Alliance Global Partners</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to Exhibit 1.1 to the Current Report on Form 8-K filed with the Commission on October 24, 2024)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1729427/000168316825002548/cns_ex1027.htm">Form of Securities Purchase Agreement</a> (incorporated by reference to Exhibit
    10.27 to the Company&#8217;s Form S-1  filed with the Commission on April 14, 2025</span>)</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1729427/000168316825002548/cns_ex2301.htm">Consent of MaloneBailey LLP</a> (incorporated by reference to Exhibit
    23.1 to the Company&#8217;s Form S-1  filed with the Commission on April 14, 2025)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of ArentFox Schiff LLP (included in <a href="https://www.sec.gov/Archives/edgar/data/1729427/000168316825002548/cns_ex0501.htm">Exhibit 5.1</a>)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference
     to the Signature Page of the Company&#8217;s <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1729427/000168316825002548/cns_s1.htm">Form S-1</a>  filed with the Commission on April 14, 2025)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>104*</td>
    <td>&#160;</td>
    <td>Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1729427/000168316825002548/cns_ex107.htm">Filing Fee Table</a> (incorporated by reference to Exhibit
    107 to the Company&#8217;s Form S-1  filed with the Commission on April 14, 2025)</span></td></tr>
  </table>


<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0pt"/><td style="width: 30pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously filed.</span></td>
</tr>
<tr style="vertical-align: top">
<td style="text-align: justify"/><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
contract or compensatory plan, contract or arrangement.</span></td>
</tr>

<tr style="vertical-align: top">
<td style="text-align: justify"/><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Item 601(b)(10)(iv) of Regulation S-K promulgated by the SEC, certain portions of this exhibit have been redacted. The Company hereby
agrees to furnish supplementally to the SEC, upon its request, an unredacted copy of this exhibit.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) <b><i>Consolidated Financial
Statement Schedules</i></b>: All schedules are omitted because the required information is inapplicable or the information is presented
in the consolidated financial statements and the related notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 40 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item&#160;17. Undertakings </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) The undersigned registrant
hereby undertakes that:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1) To file, during any period
in which offers or sales are being made, a post-effective amendment to this registration statement:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i) &#160;&#160;&#160;To include
any prospectus required by Section 10(a)(3) of the Securities Act;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii) &#160;To reflect in the
prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment
thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement.
Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered
would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be
reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and
price represent no more than 20 percent change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration
Fee&#8221; table in the effective registration statement;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii) &#160;&#160;To include
any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material
change to such information in the registration statement;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">provided, however, that paragraphs
(i), (ii) and (iii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is
contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange
Act that are incorporated by reference in this Registration Statement or is contained in a form of prospectus filed pursuant to Rule 424(b)
that is part of the Registration Statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2) That, for the purpose
of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide
offering thereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3) To remove from registration
by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4) That, for the purpose
of determining liability under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant
undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless
of the method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of
the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such
securities to such purchaser:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i) &#160;&#160;&#160;&#160;&#160;&#160;&#160;Any
preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424
(&#167;230.424 of this chapter);</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii) &#160;&#160;&#160;&#160;&#160;&#160;&#160;Any
free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the
undersigned registrant;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii) &#160;&#160;&#160;&#160;&#160;&#160;&#160;The
portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant
or its securities provided by or on behalf of the undersigned registrant; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iv) &#160;&#160;&#160;&#160;&#160;&#160;&#160;Any
other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 41 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) The undersigned registrant
hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant's annual report
pursuant to section 13(a) or section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual
report pursuant to section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed
to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant
to the provisions referenced in Item&#160;14 of this Registration Statement, or otherwise, the registrant has been advised that in the
opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore,
unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses
incurred or paid by a director, officer, or controlling person of the registrant in the successful defense of any action, suit or proceeding)
is asserted by such director, officer or controlling person in connection with the securities being registered hereunder, the registrant
will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction
the question of whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final
adjudication of such issue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d) The undersigned registrant hereby undertakes
that:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1) For purposes of determining
any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement
in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under
the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2) For the purpose of determining
any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial
bona fide offering thereof.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 42 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Act, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in the city of Houston, Texas, on May 12, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td>&#160;</td>
    <td colspan="2" style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CNS PHARMACEUTICALS, INC.<br/>
(Registrant)</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="width: 50%">&#160;</td>
    <td style="vertical-align: top; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="vertical-align: bottom; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ John Climaco&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-top: black 1pt solid; vertical-align: bottom">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">John Climaco</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer and Director</p></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Act of 1933, as amended, this registration statement has been signed below by the following persons in the capacities
and on the dates indicated:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 27%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURE</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TITLE</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DATE</b></span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ John Climaco&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</span></td>
    <td>&#160;</td>
    <td>Chief Executive Officer, President and Director</td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 12, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John Climaco</span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Principal Executive Officer)</p></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Christopher
Downs</span></td>
    <td>&#160;</td>
    <td>Chief Financial Officer</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 12, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher Downs</span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Principal Financial Officer and Principal Accounting Officer)</p></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid">*</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director and Chair of the Board of Directors</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 12, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Faith Charles</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid">*</td>
    <td>&#160;</td>
    <td>Director</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 12, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jerzy (George) Gumulka</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid">*</td>
    <td>&#160;</td>
    <td>Director</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 12, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffry Keyes</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid">*</td>
    <td>&#160;</td>
    <td>Director</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 12, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bettina Cockroft </span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid">*</td>
    <td>&#160;</td>
    <td>Director</td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 12, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amy Mahery </span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By: <span style="text-decoration: underline">Christopher Downs&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Attorney-in-fact</p>

<p style="margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="margin: 0pt 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 43; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjU0KwkAMhU/QO4RZFzutP4suLVrEKlJE3I42ymA7KZmx6pG8pWOLGAIhee/LEyIUOS11jQzHeVnAHpu2Vg6hxAsymjN6R7Zap+BniVdtHSvj+vUHZuQZ9MxsJE/+3js7bbFKQU6ieBwlU5CzdBrDbiOCr56RuegKjdOqBmUq2DG1rNEpfg0f9upJhppXn3RAtppMCvFIDvIbEhknsKVOPYhvFooiE0HYVyBypnvrXYunQ/MlYVFj4+PsQP87+ADKpEpb -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>2
<FILENAME>cnsp-20250512.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kopo7xRiXgen8uEbXpMOaaN6aPty552iYkxvmR2fRmqfysu0wSajy6oyZF2MckK -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:CNSP="http://cnspharma.com/20250512" elementFormDefault="qualified" targetNamespace="http://cnspharma.com/20250512">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://cnspharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="cnsp-20250512_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="cnsp-20250512_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>3
<FILENAME>cnsp-20250512_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>4
<FILENAME>cnsp-20250512_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://cnspharma.com/role/Cover" xlink:href="cnsp-20250512.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://cnspharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( $PPK%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( $PPK%K35XUA[@   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DL%*Q# 0AE]%<F\GS5(/H9N+XDE!<$'Q%I+9
MW6#3A&2DW;<WK;M=1!_ 8V;^?/,-3&>B-"'A<PH1$SG,-Y/OARQ-W+(C490
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MM5II ,,X?<D3$L/<@HL(2W@4R]9<X%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A
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MPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE
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MU\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U .EK
M>MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ
M!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.
M\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( $PPK%I&QTU(E0   ,T
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ 3#"L6M-7C6'N    *P(  !$              ( !PP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ 3#"L6IE<G",0!@  G"<  !,
M     ( !X $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !,,*Q:
MO4)1[>L#   _#@  &               @($A"   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ 3#"L6I^@&_"Q @  X@P   T
M     ( !0@P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !,,*Q:EXJ[',
M   3 @  "P              @ $>#P  7W)E;',O+G)E;'-02P$"% ,4
M" !,,*Q:JL0B%C,!   B @  #P              @ $'$   >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ 3#"L6B0>FZ*M    ^ $  !H
M ( !9Q$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
M3#"L6F60>9(9 0  SP,  !,              ( !3!(  %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&      D "0 ^ @  EA,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001683168-25-003362-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001683168-25-003362-xbrl.zip
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M^0.K%]/)1W-"((1Q8(-E<X/M6KC/FIUF0SA93MYV$/U'U+276O/%:"JD8QT
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M&&%&$_KYR%=PEX*HH<98%K7H[%^+8<1[.)8#?0]!A,#Z2$Z69/1$E+IW+M)
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M+^J,)4+K"B&_@$5/XQ$&?>EN.!3(2,6+X?3P4.L6Z+FF0!1M+UP9+1N^SKL
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M%ONB)QQVR$5L,4NE5QIEJ 3%:*E9H/V*F#,S;0J-NRI+JT@]B'FIULI@#ZG
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M)2%/>+=LQTMC2@1ZS.1F4&(/.]VITC'E?<Q%0E]5?E'O:AX#3C]U)J6T:6Q
M@8V?.<L(SQ8FC&*J*ITE=OJT'F=WGQ(5JS['RYJ4X^6H3"LWYE9F+%P-.%GT
M$*MF*5XMVYE0\@5V-*'M+)F7+#.XN <'.EW(&1",UZY%X.EZE/)3DLOTUW[H
M#[.AW?,]*7>-: ,5(LL'DKQ\[K\(3,%/QX[EPBI))-V$GR^0S9W"./^Q1UU[
M7(FR[J>I(+^4;/;3%W2]W/)A(JZ#7R:#,3<HC)D]53)F8<ENA:4Q>*<Z0POU
M=#P=WQYR=PL-@4DMK3B!KU;N&:M8D%S8ARRBILDY4W Y+4.KJW): PKSBV22
MC_"#,_K!>3YX!=X2&5ANS&=Y",XS$-2;FYOM5??-:O>-/DO&'.RZ.2CN_*GK
M;$H(=X-1$XDP(-FU,&.$9JX>QH*F526N]Z8P[2,>MF:NA%DMN96Z3FO.O=+]
M6G(%S=(-.&O2D8?470<T&D<)EYJU .OQNG LC"[R95A,I*-*N7/_]NQT-E>]
M-ZL;;U8_OM'$&/+-A?.%':(0J?+,#46@FG9)M((+,4IEUZFVA$^!,\\$^E(;
M'.HV7Q9'VE@UO$C=P0 O,B\A#%2,H5&W%HX_5/BB;G[ 1OB]3I0H3ZZ]VF?>
MNQ6ZVAFD"M)!XHK;''!QM4&4#.F.9,U#F9K"PKLI1><(#78L<6=Y#/TZN_ Z
MPGTU,<T)_(&[..#WV(ZDAAV:7XK+$//[J-D3HGR@)\BCG%I="8WF#HE=8V09
M^339I'8)U]]PHFZ9YR8*":< ?CL]WUE3\!UW.EBG[C3=K4D\9S^0YZPIYE=F
MOWO8SGXHVUD+8#O[06QG+8+MJ!]RF=W EA2^1-=/5,U?#T?'^ H'O8PI4V@1
M%N^0] 7XC^IW@5+YLTA362.F=D1A3$0CM/VS$$4+K<*_,O(SV-?<888Q3 NZ
M(VHF5.,)RT&+6%%36-2^HN@+ESG(CK)F!S5N;*L6/6\K"+J)$*F"]IF@/D^T
MVJ3J*;T0QK7%VT$>$-Q+MNEHLUJ20ZBB=:)**<&6I/U%A>T#:>P!#W*S2^08
M%X.F=7TDBJ6%,JP76Z!]W:#ZH *K4I$Q'6O(848/P?S=%">4[X:?LA\DXHH_
M[E%5*MA2N$.AN'(9[UP.1>=']OH+O6)]1;4G3;YFA)YA6*KLV5+#2T"J@M%#
ML]=-_P)LK8BS!F$0C86P5 NMOO08J0=\V4&%%S6?J5ER;,R?V$SR&+OH*J[+
M(M(,]OVBNFH*F--RY-F<TL)".SI.IOD][PRGHQC;D_O[^MC5-0YU8VO3+\:3
MNHF";$AI%5.]+">V%T= YIHG@*%BKGB1]IELC<BL0?-H;CR$(IJ:N7)%FZ6]
M?&;CIUQ:DO/P$_=@YWN.>"+POS/&![;M!+*E5@T&(9;%XGND.JV<'K>YPT*M
M28$X2\K<@B?CQ5M[RL^%=PL,X%ZI-GGJ9H(]=3URD\>"VK-2TAKN>Y:#S=Q3
ML>]H1RKJ U0PS7?Z=72+.Z8*_]40CO8IZT'5CWLJ$B \*\D(E)L<XJ_ ;=2\
M/5:^/5H"& W!IMTDA:=N&KFY&D>OHYI70U%Q$P/S7/BQ913MF@Y_N(;Q!)NM
MB ODH-+-'<DS3$0A) J02(1$@2&@OFMR&PL<$E6@&AER3M;06KD0SEOMXLQF
M85DN=<?6NX2F@3]%)KS!3E(8W0%5.V580@45!8_G36<5#H25J<[FRI';X]B'
ML9VZ^A$&P89RU#%*(W11M(>O.6Q\8<0]Y@=K40*RX$YA$6)G3 ED\5KTRR?.
M_G@],YV4Y])=YKD\?I[+]C+/Y86?-R.F27>CM&Y-DU'!*>$5A+<@]\+-NQ2R
MJHSWH#\<N3[?Y#K\4S'7'D,I:Y BCQPO;E;;9!A7K:SI4K X0(77\9 BOJR^
MF#8K+BD80@*]C(YI 3FR-3C;U:IM4]Y]G+"U6'F3\$05_X DR5+> >T9L)5G
M0'H$$#5(]%)]WR<,?\F_HA3L*S.42#$(<05#H6X8HA:I01<2F%"?+4"2G4B8
M\KN8;89QWMCF$ETYGH]1#FYL6N_<8:N[AH\UM)FNSP 5-*0EP7SGF%*>*8^9
M(X*T 6.+P,@(VA2')>1C=C-3CU)R(S6M)JIWZ (DU+.J0Z6B7^-90MR,F)JX
MF9HE:/5!IGMXL\YZ6QV31B#E_ K[PL*2<DLVQ&K%SM'4&TYMJA^(*Y$P>#:2
M(NZD-Z5T;/]^RH8A_"K0(]A>&JX"=/YXLI9 6'C?)$)P40^=X4>R,9^'Z%*)
M+R'&^6"%?,P^2Z[S=;*BJC/*3&8#LT4NM&JBB\N,8JXXCK)8:]?[[\N'9SGP
M6P5YLR@3+(UIJC,+I82PM83PN64Y?'Y%/<IZ4?2=[^4GO(.?LB*F'FY[,M2V
M2F L@4UK7U13*Q'1@/G?/*;**2GZ$3#]E9PC;JB<7Q2CI\)++M3!],KZ?2["
MB%</)A7[7\&APWM)^O CJ]2]8#\A!R^U<E )!HK%-,H8>KDEJ!]G-1B@;&4G
M2OX+G#$IDB!3BA$%T&(2*Y^T@@N4"4,H>&K&I611C++22_ANOA$YH"&'$5S3
MH2%QU-EI(L$(Z7L,"*38F;S6D[*]LG<HU\!PH5@]4%-N35!03Z0N]3>OXKOI
M-51N4-#O,'F4DDBYUP5V24Q%M8ZMI'BH<E-97:K3EDV,!E5*1T%&HPB_6 :>
MV$!_@=N:V+O"2]7M@&E8'/RDB0W8&Z_G_62"W/SW8PCU/ZFIR"VJO-?^2/79
MH&7 :E.SR[NE]$6=!BAK4K6F+A]PJ.Z>0GE8F@=LG?BZ5I+BY&$H&;FD?5,U
M@$M?/4Y:Y?.Z!IK-7,<R+]$\3%HT2B3&+[&_*H-/,1.VC%L,6LOW^@ L.7*I
MT03R!4AH$DB)N:56>4L-(RC?2LYUA"> K9(:$X.R&D)R)>&U0-9:43 KLE3"
MC/DM2Y+JL38#8Q3VDV$:D".PT.@ER7E="@IM4)A&#J<N<(XF/.?!;C#6)0AZ
MCE9DZ7444]+GK4+A8Y:&B=U$>8J;.2JMHLRVP,J&F*'093B"@N,\[+\1KR!#
MG$1YQ"KEY0PG"--&0%JV@2PDF21S(&086.%*DTFFAI9)*TP'=RA9YV3!2?V:
M4#9OUCQ4H>)3$4I@,M'%K9(%"H. '744MQNZF']"%2B\N05;E%::K@V5R< 2
M_(9,<^%2U#C)-8T2JB-!+XK;8*Q$69D\(UI?9Z,R<J(V4A,1^GP>4FI3%0TL
MHY1?Y@-<TE=3C,;OENBLCFWD%MND1B0<]-?0F H3([=3.)T+)([5DWH)#*\.
M;#]PN6T'VDH$_Y'_4#L_/ .RF+A&+7Q#%)P3LQ3DN9H<9R_D^HW%LR?WR"QK
M4<G$D(52U,\=*)I 7!Z@I<>E$P?%C\7MOTH;#[(RFA3QI]R86/958<6#0WAF
M(8+B1:, @<*1ANJ38U_5N"+_?O>>4CM,;%>IQM7"N5KWX:=R"%8A<]> *OR=
M8^Q-"+F\HM:/ >5.7EF=DGX_D*XU)9 N_('R#V='SVT S56@NE3'V(_ @H-[
M5:]*,@;C=&AZKHUT-H:U^=*(LSL/?%VKC*_[TIGTD03(_='6]66T]?&CK3O+
M:.O+.D=T$?^F529^)V@A_(>2$+,F@H2SWSU2JA@Z_PJZC.PSQ_4'("+'[!:(
MQ=,$8)_NQOY**U"KIUKWXK&K-9N@EE8:ZY%R.]UM2K>95<BB*^UKN:IA B'-
MK?YFH*AE?9VB46#C= I3P=Z+RFN:&DA>10NBEFT1?\IR$ZX*9&N4&CK)$C5*
M-P!!+RO;J-I?0]4:6);X]=_@CF>YP<6I4I,S:R4E+@1A[*I\0,LHX3-K8,O&
M\6P-(IO.B:,LBL+^TR9B7%W6P.O!:_FQZ0BBPJF<[A@4Q$@ 0I'YB6I;\?>6
M7_=LNU78=GO"ML^C0VBC8BV[R%&!$5GE.2<DU]7-+PC <<XN=AV[P"/#"6S@
MJ(151!3@2 ?(S[X?][,A&OWHVV ? 1=^F:VP*)-?AYM'[EA6\<040:,/$Y&"
M!"N2K994NRZ-F!C+]!JH[>*REQ:)7- <^/J1?=""=R!N"4T4<8@*+A+"I;AV
M/9Z0(B!OXRU3E*<S!E$FXR+E>43 IY1\;'3\LDJEW77B:JY\6]PJK0%9U,-7
M1_L*3YG%RI0\1#4(F#DD&(/"K LS>-3#9F8*-P #;CGB!WWEE.J)) -G(RSZ
M45%"N<6\%[HE?;6SE8Q-JH@1>W 7;</6)9H\JM-J>A&$>AKP4!9P<1>F.[BO
M+B7G_A4S''S%;H/RCL$2-\%QDEQ+*WJ=\X!.* 6&#K?0L7(I3,# 3#Q"7'0$
M2UEG:?\WMQ"$TXDN\"'0PTA8F.T3IL7?5G7RJIMXX-\)B1S1LB]D?T-T2SGT
ML.!0GG0.4W-S#-[(^(EC6@MI V@PE=5*2F90JHJRR4VKC>.1DI_:K7:[8V1K
MX Z6B"IO\@((LDIX+!A(=(.\*V5#+D"3P*ZD+7R)8A&1T,V1O*H%-E890*9I
M2Q2RB[DJ2F!K0#<5E)B4(UJ';8/K9!6'Y=4@,.*^T%=G[;+<FY9JO%*O8V47
M^:VP8%;-JVL0_&O8Q)&K%$K@.3P1JN#*3_,W4$%^' W\5 .6U_*?9:I$!0NO
MVEM^\=KY8Z=R7,J^*%HS-?4>74>E^-TZB31<3-Y9M1!C+_9I%>@G];3?7Y4W
M<@H!A<3U*#J7&36\ /'Z"Z.I] )5%&9ANF4EASP4;KR&F<XY:!X]]S?W$%$J
M8*EM+B8=<-->*V\Z/:^NMC4)7 TD@*"(0)Q<<0Q7@B(:"(C&H%1QEZGL$)EP
MKR-0FA0#(_UAO7];EAD#TQRF&-LP?'+:=%1<\;3R5X9YOHG,I=$9<87U4<6=
M:?YJ2[TQ[T7/%&N2JN\@N22AI<HO855=PIJ7QG0:^YA;NN*1V(1L $IG9LT%
M\YL5M@?RC (XJ*1UDCFKT^R&[ITA)1(#%(K@1,C<(M0%Q,4S3#U*<;FW67->
MGU/,L32R=_+-U_.3*IO'7=E9*.69FY*EK6*_>.X\S68MVL=X8Q<S,95A)75/
MV9.Z7CPFV8#17-@3FHT8594L(P7*8>1/64W"K>YI/((90;G-0\SFXQ*/,*1%
M0X$-YW^9R62DDB77,#FFUZ3R@M3KXJ]IR$+U>U[)@@E/ZB^6KF-Q^]BA05FJ
MV6(OYZ=.?)!GI>3Y >/"E,XE;<8\)'"4.6DXYK-,K8[\V*,L,EG8S8HWEZ:_
MPBS*.J-3 D9QF7TY^UHK3)^ ?UV4J\#+EWDJJM*=5HUN0G(,E2RO$^CQEN9B
M-]XS";="Y?7<<0YO.@N,RBL-<AQRKA6%)\8L^?%6=#@==L 7H<['&D6<>DF4
M<Q9A47I+N4OIA$DB6!\HOX1O8C.5$T6IB^95PF-3BC@)\LWVSW4QGC<.UQ&4
MB@]DT"2/'^7V,AET8_;+ZDPT) --@&PX+( _-&R&0II"RU*A;]4<'DT.Y[N7
M<O0Q"1G=J043DA("UB[Z, &16&QKX9:#J4YN' 06T'VK*QO^1M&=8KE>+-#)
M2$<PS-V9>$68#K\2J88'0!MY#:M@B@0%=XM;7P>XU(!W^S:*%>00[6[AEBC)
M&FM:6?,$2.VFC^NUB+@I<F VECDPCY\#L[O,@7GAY\V(;^O"9WEI#((,[;%4
M&-%]JU!1)-.4&7O?M&<:(?A?IW96]BU6(,OJ< EO$?!3[0'=4WY(R2CH/H0'
MFC/DL1^#0BHPP#!KFD?DO<(L]7Q/C".),H6F6AP%>5BA3(V"EM!Z# ?)T%RD
M"A1EL1:P!WN"'XL-"TBAPZ$.QH@6"CX3%RYAO2JOMU6PU#D47I$T#N]23CJI
M!4(!C^>0DD8^O;D[C#=(%3M6P8AG^ <]/Y7*7WAM!*<D- *]6:C4Y8@U6<1K
M(HT(-1ZIA4D]A,%G=9=0TJWP6.5OM/B-C/8VS#$M@=^P==RX0(N#VW5+]GRB
M(1 %+$ T]/L.*&:!3Q>,8Z!3Y.J2$4E"!P)52I*_DB'_+*H#X+SC1&,!JNQC
M&6/NEPFJA9:L=;U7,26/\]X.3FDGK'RS308!MH W$>J8']:^A5V*S&?YGAD'
MT-C_?@"6A2IXPJ5CGZ!V!?4$,2TW;]7.K13N3ILP]]4/="4]5\^#;-&O,!Y2
M+6(S50<BZWW]L%!:WH\2&7>!*TNP,\;*,<MT+!M3N$(:F#18EA=&8Q8"FTR*
MG2421-W-$BQYKD":O7#970@?% KZM9?S_E8T#(321X?TW"/<SRB878Y!EOL5
MI=>U?>U+@3-9"8W5M444!3_1?C?/D?7GBM,Q=T:A*EAJJ9O.<E5BT.[JG]'N
M*NF?IRI.\GJ_V,TL]\4QX$&,@C>9U"+QA8R2L=P=C&)&%KU7"N8F(8*\GG2/
M;\*:N,0R5F2L="T(2UX8% L9)=>]A71))]8C9[*D[RJ.;M-K-;06S):\C0AW
MF:PZ+NN#0P#W>NZZ,>H=P5B-.?1? (DJ7%-VCM49RX;I96!KKJX4LK;2*L''
MU,#0M.S]T(C.*$=7'<R/HD)G?['28 "JJG6H5"];NHEN#N/5X"%R#$5, U/7
M(8(Y6ITRKU"I-QF]=Y4^3=#O]>319GFP)^A6%3<NMB@KY#*J]R/8J@!ZF5!&
MUG!J8DUJB>CC"/,F"<L+GT25PK'43U5@<G&(/@M,"IB[/O"JAIO"E;:Y=*4]
MOBNMTU[ZTI[\>#1L9[FI[*9N*GNP__7R^/1D__Q/^^3T\L@^/_IU__SP^.17
M^]/I^3?XX]KGT]/?\>\7E_N71U^.3BXO7IO_J]C2"M5P-&]MF1*(*'ZW<#.N
M!5'TG6%)=-]2&;VD[K,%T[>A5RQ<GT&A\:E\68/S2WG.7*,7%R91V/ @-@1"
M.!F\QM&;$M-EV41HGNQ@?(A=<F*= 2&18O#R97W&!)M1C22U7J*"GHXEOZ+0
M5"80-"+Z)[NTR/YW](P2QY9Y91&Y,/P;[;A2*.:4]4^%ZT([?5B75/ZLPIQX
MW;^'T6UH\5K3GU7KVF*;WESS\8?HY:)8I*$#&18V*8^<ZJ-5K8+S"[^^QOP.
MR0;D-,S#?A8V=R"<#1F3R]7EJ<:#)8#G$O;+^=AIB-V44B-JV.27[O>8T6=]
M"W=OHA(%<E-0M>2P=,XE)>+H3AWR8^RF,C0>UY\3]Y4_90.H_"DP3/DC9/#*
M9VC=Y&-:^F,Z)^6GV457&4/5B)2_0(VZ\AEZR,H?]NL^Y)[09<J4(\*HG+(3
M?^ACWI]D3;8E8@5AQ4DS:!7AGDW@41!4 4(W7%VS!8\):HT/6U(Z(M^C:T4.
M3_ECN/G:QWV?W&L ZS$;4/>B+'WWQ =H)M5S>MH*FJBI.+5K%*<IM-.5/:NJ
MZ[5;79S0VQHU4'Y5[#5/&O' !:8:@PHZ'O:B@%9C9SWO,E]4*NO=+(UC3ER4
ME;V2?R#JL5^CF#HGR\PD;HHE6UI@[R(#4[I(KZG//A(K=3JXPD7-=LE-C\I-
MY&:6*9R2E4"YPAPE[/E(K6AN7)4$9BUY:,E#]3PDVU%IGVP1,]+6>/E!8(TP
M>XYC&>HI ]K_\1EJR3E/QCGE-J=Y34@B$R112PL"028-BA\P/N#>"_R^"!.1
MJ%"9RB3TEP)IR58K>RX%0 )W+!-[]'T&IKX//T*S0%UM%M>"E*XU2NM]%M)I
MR5W/C;M*"CC57<?H6D) W*6FO62;>K91>65<HA3FV15+=EFR2[UJ)%(_3R[3
MX.*27R2:SZW^NZ5]P8)J@I9<M.2B'*%'29E MXSM!ZX_7,J:)9>01L-I/)1<
M3,5C8%*M<7$6_"##<%,6<_F_A17* ;5=,+XRK[(E4RV9JJPF:U!QYAL)FT99
M)[U(E[:S82]["7#,P\R>6_+5DJ],OF+,(\/[(S/SY0-4PQ"A5$JQ\,#T)=G:
ME\1(7DO.6G)626*Y'M9TIUA1HS Y9"H$)W8L66;),F662=/8[:OFAW3#?1=C
MB800BH A0T-J'F6DE^=XH<%XR55+KBI"_P32[@>UG%N*4%[+DDV6;$(MYS#K
M2X;,\K1(#,EF#(2I@*XL\B*5*[&>EHF>.!GOM;UWB@*%K66!PA,4*'26!0I_
MRP-W7Y8G87M3?P"9:IOW+L[Q^CB?&^OZ.=.:Z_45SJDL0$\8-->X#+"*#^%#
M/ 6S/B&WU4HB AWAK%K5M[Z/\,)>1M!DG*01W3=2R]XO9)\353>R8 "'YOQR
M$VA*7DMJ2I8QI3RIOFY.DW/*>06_,Z8D@Q"XL@_ Y,3; -.8@[&E2BLEK'^!
M#@8>IRQH_CLFX>JZ4IXO^2;BO'FF :U(E:0YJI8R YRZZDDJ#Z@44.:SDGG"
M7DUM@%RCODL]-]UX;%?SB^O*-YA>WB\N*V 6M(J5 ,;>8JII\\;>5X:B=^IT
M(F_)XFDK%H- X5OD\0V8/EI>$OY54FJV%W9L1LJ#/QC0=_"W?T; <C9.)(L5
MZ(9"U4G4020"7X^F\&<N#."*\"H<HB$**$M+M2#E"*11@U)B& E7:?!(J=SD
M5K(#'S9B<E4QGR2(14-EWSI)C"!N1@1R1YM>9!W+% 82"MS-:X"153!\ZH=4
MS<(%P,4CK'S0MWXB'((D'Z6,W"+Q-GN4(AN CH&:3>#>SA';P+0*:(L8PA%H
M?0>31A @D&=40:>8I+>G]?DE$4LBED0\'R*JKY]DA&TOC; G,,*Z2R/LA1[%
M!B:8X7@6:M"W= WZUX3:UIQ)%]JB*7^6JB#H8*KD-&_I$A)$5-&Q*.PB2#X"
MRF"2]1W]%I2]G[9:&_80OB)5BS0Z>EBC18E"DX"\TTP68P.CE'']RC"+!#GE
M(<1_RBIHM>.$:FJ@)^+E@Z.J2:4$(W?,[2_R-@"@\<G:<V[-P_/-86+TQ.N[
MVFG4=:,+6T\W?)BAPXK1VX>[4\S8(L+ZH181-2NJPNQZ84U^:.H88<VW8X2$
MN.Y'#!!U)?2T<O8H@?ZP+6>IS@W%+A'T7NRM9DRE97\DIX%\%QLA!O,P2EJI
MBP6]IWADN$^#L43(.99"9T?"MS=_=A =G1FON_GSA'X7Y38KL@UB];QMM';R
M\_;3>JMKG#YXRT^=UJ;^Q)+->"D(63E6S.7Z],SK@&D9 #RMNI19TH1OZH1E
M_N:>;I+<?P8^[!%017UCK[P+V&JA&Z0ZO6\F]M_BAFP*],G+\CZ,"\&\>QGW
M18ZZIE ?Z^X+DX.I"7(4D\='0W/!$ H0K!_%HXBP4>$R&$4)P\12BQ(I7Q*C
M/Z<Z>Y(K8'(AE9))'$[9[]*J(PZ_5/*AAD[V(5*S.>(WZ1Q$3T.FBQ]S?Q[V
M_KM58('4,R81\0VC8X"PB_IX5"PEVW 1=-\B-4_E#9:]._G[,3M@%$C(V+Z.
M;FWJ(RU"W<Z3''=Y2Z6B7-N7[Z2;Q<?S9*E&#WP-T+&%ZX-\8B6@MQ"D8!S!
MA*6GD3UW!AI*WK&!,74-1#FL5<?T4254ZL3BZSPX9X+K]J5'R6A@8146R361
MI_,;)S]T[+XLZ"SR3O9#P[>Y=A6["#"AL(?!!'&)R0NMB1BK&&2?&*N&A=39
MQR'NH^LSY6I>X ]TJCH,R1R3=SNVKS(7)2:6F)O5G9(IO[8N6O857N$AMSJ1
M_?AL:I8A&_!*UI<A$DOY\@KSXVD)B4DX1D,'VV6Z-Q&!8=/ I+,!&V9Q.&>V
M>@0.6K[BV;YB"H_.SM*C\P0>G?6E1^<Y'Z-Y^6NVM;_FT \HUOG<7$QJ]9[(
M=71,W4*47B#3 ?);WBH;E(YJ+L**@39V/%Q>"C5+]/!@K'HMP%M%WE53A?7Z
M&/-.;Q']/VWLK$S@SKVQ9;;SS-OQ-B"?KS9T2W\C<V^Y.439:J,6G17S67I7
MR&GBX4*"3HX:5^J&5SY9K%'T779,UM9B38-N"7[^.K77?5J00S"="+-^O>/8
MW79WPR'<((J98GJ"8%=1W<K>PD,_;9D^"E#9?MIHK6\;)GIIS5LPCWOVR; 0
M"08KC="VU#_AMG8.>W_R[U65I"\H70!ALS6.88[*'V6I"GT;3%$#R$V<<07#
MH#^$$C_0)==Q-M?;SDYWL[&S.&+[FZWB#J@UQUCWG[AP@6Y[7Z&/DP5Y%4=)
MDBO&V'5]M]56JTK.-FZ1C:5\]?M%';(Q*#YYLSJ;Y=W:;'6V)NS64YZ&QWRK
MNH;HGI[V'\.3,4&$2D=OOL92>IJ2LRS@9B*C1A@V<D'C3AN-(/(NX;-047-B
MU$VC/*9;3G>S[;3;[49YC,["/G>S(7>#],K/0H>^.:J71DK]?.L]PGCH.JU.
MUVSO(7U/+FWO3$0HMWUC3P[;E*^Z3 #_],4=VSMTLC=Y/4K1DEG((#%TBRJ#
M7$M?H6G.YO@EIYB/6)JI9+%9*1FP,2\+1+E;DE)KFGBU(/>:[JE9B  9:;.0
MG.:HL(L^;X;T4[>UOIFS1\6;.>.9S54R3.S3#5V:J,$&&CG']-S$YXNBVEA@
MUG\[,PL;HB5?S'D2P_^&19Z)*)9HB(=(]16R^H8.&C>D98[/5]R3XGY.5#^8
M7LYF4_W@Y(50<NBYVB\XHCS:6I6<XR;>0VZQ@7]%'F.9KQ=&6E[7*.M2*%)
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MK5>PV-WMQO2HAI6.1ER@0P5FTRWU^CJF8142-56ZDQJ-$H])=W:Q%Z @96<
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MY2FE'9VH[_RM\;$^..$7$8,*Z$N1']'(>&5WG'Z\OMR79L:+)8X;PAJ#_7?
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MTL,/?(K2,/5V[:A409?N8]YKT$ ;:^?MYMWX-N)19F=6@D_YEOKD@Y!9[6(
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M&L_2>.-9V%6(.="JMU4OR\G)$V5-%2KBMP8HIT8GF_55ZH^3D[G1XM)U<VE
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MJR;=-#(?'QTW&7#!;2X3Y,?_%X6NGX!>Y+B=9=J5D0Z]8>J8/((IT3?R#'=
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M>S]ZH)!(ISW*B_\FO?&B^=XX:OMA1[WFS%^@ =(.Z=\[/2R>H8SH*J3#&EE
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M!.>&/:,+JL%WM4#+SM7D\@]02P,$%     @ 3#"L6O-;FUC]"@  ?X8  !4
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MQ+2DE!="^\(BZFE<J9A$7$Y-S]F8%H>Q"'\0?&/=;=EJ;BG\@ZZJ^.*PR%T
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MR19351_7RL+HXK:A5@_GWVNI\?%%5ME=Z-TC9_ # FV)JYZ&S.G>-LN#Z''
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M,6$Q+FAT;5!+ 0(4 Q0    ( $PPK%KKG]T;)P,  .4+   1
M  "  >'&  !C;G-P+3(P,C4P-3$R+GAS9%!+ 0(4 Q0    ( $PPK%KS6YM8
M_0H  '^&   5              "  3?*  !C;G-P+3(P,C4P-3$R7VQA8BYX
M;6Q02P$"% ,4    " !,,*Q:&%SS>%4'  #65P  %0              @ %G
MU0  8VYS<"TR,#(U,#4Q,E]P<F4N>&UL4$L%!@     $  0 _P   ._<
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>cns_s1a1_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cnsp-20250512.xsd" xlink:type="simple"/>
    <context id="AsOf2025-05-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729427</identifier>
        </entity>
        <period>
            <startDate>2025-05-12</startDate>
            <endDate>2025-05-12</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-05-12" id="Fact000003">true</dei:AmendmentFlag>
    <dei:AmendmentDescription contextRef="AsOf2025-05-12" id="Fact000004">client made edits.</dei:AmendmentDescription>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-05-12" id="Fact000005">0001729427</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-05-12" id="xdx2ixbrl0010">S-1/A</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="AsOf2025-05-12" id="Fact000011">CNS Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-05-12" id="Fact000012">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-05-12" id="Fact000013">82-2318545</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-05-12" id="Fact000014">2100 West Loop South</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-05-12" id="Fact000015">Suite 900</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-05-12" id="Fact000016">Houston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-05-12" id="Fact000017">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-05-12" id="Fact000018">77027</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-05-12" id="Fact000019">(800)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-05-12" id="Fact000020">946-9185</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="AsOf2025-05-12" id="Fact000021">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="AsOf2025-05-12" id="Fact000022">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-05-12" id="Fact000023">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="AsOf2025-05-12" id="Fact000024">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 12, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">client made edits.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CNS Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001729427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-2318545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2100 West Loop South<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Houston<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">946-9185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>18</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="cns_s1a1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cnspharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="S-1/A" isOnlyDei="true" isUsgaap="true" original="cns_s1a1.htm">cns_s1a1.htm</File>
    <File>cnsp-20250512.xsd</File>
    <File>cnsp-20250512_lab.xml</File>
    <File>cnsp-20250512_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="18">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>21
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cns_s1a1.htm": {
   "nsprefix": "CNSP",
   "nsuri": "http://cnspharma.com/20250512",
   "dts": {
    "inline": {
     "local": [
      "cns_s1a1.htm"
     ]
    },
    "schema": {
     "local": [
      "cnsp-20250512.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "cnsp-20250512_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cnsp-20250512_pre.xml"
     ]
    }
   },
   "keyStandard": 18,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 4,
    "http://xbrl.sec.gov/dei/2025": 4
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 18
   },
   "report": {
    "R1": {
     "role": "http://cnspharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-05-12",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cns_s1a1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-05-12",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cns_s1a1.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
